BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27-S34. [PMID: 15508094 DOI: 10.1053/j.gastro.2004.09.013] [Cited by in Crossref: 718] [Cited by in F6Publishing: 658] [Article Influence: 42.2] [Reference Citation Analysis]
Number Citing Articles
1 Deuffic-Burban S, Mathurin P, Rosa I, Bouvier AM, Cannesson A, Mourad A, Canva V, Louvet A, Deltenre P, Boleslawski E. Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach. Dig Liver Dis. 2014;46:157-163. [PMID: 24119483 DOI: 10.1016/j.dld.2013.08.137] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
2 Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology. 2008;48:137-145. [PMID: 18537177 DOI: 10.1002/hep.22312] [Cited by in Crossref: 182] [Cited by in F6Publishing: 266] [Article Influence: 14.0] [Reference Citation Analysis]
3 Thoppil RJ, Bishayee A. Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. World J Hepatol 2011; 3(9): 228-249 [PMID: 21969877 DOI: 10.4254/wjh.v3.i9.228] [Cited by in Crossref: 155] [Cited by in F6Publishing: 120] [Article Influence: 15.5] [Reference Citation Analysis]
4 Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137:110-118. [PMID: 19362088 DOI: 10.1053/j.gastro.2009.04.005] [Cited by in Crossref: 392] [Cited by in F6Publishing: 356] [Article Influence: 32.7] [Reference Citation Analysis]
5 Abe K, Thung SN, Wu HC, Tran TT, Le Hoang P, Truong KD, Inui A, Jang JJ, Su IJ. Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci. 2009;100:2249-2254. [PMID: 19719772 DOI: 10.1111/j.1349-7006.2009.01309.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
6 Chan ACY, Poon RTP, Ng KKC, Lo CM, Fan ST, Wong J. Changing Paradigm in the Management of Hepatocellular Carcinoma Improves the Survival Benefit of Early Detection by Screening. Annals of Surgery 2008;247:666-73. [DOI: 10.1097/sla.0b013e31816a747a] [Cited by in Crossref: 68] [Cited by in F6Publishing: 17] [Article Influence: 5.2] [Reference Citation Analysis]
7 Takahashi H, Mizuta T, Kawazoe S, Eguchi Y, Kawaguchi Y, Otuka T, Oeda S, Ario K, Iwane S, Akiyama T, Ozaki I, Fujimoto K. Efficacy and safety of radiofrequency ablation for elderly hepatocellular carcinoma patients: RFA for elderly HCC patients. Hepatology Research 2010;40:997-1005. [DOI: 10.1111/j.1872-034x.2010.00713.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
8 Aronsohn A, Reau N. Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients. Journal of Clinical Gastroenterology 2009;43:661-71. [DOI: 10.1097/mcg.0b013e31819f66e2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
9 Ibarra RA, Rojas D, Snyder L, Yao M, Fabien J, Milano M, Katz A, Goodman K, Stephans K, El-Gazzaz G. Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. Acta Oncol. 2012;51:575-583. [PMID: 22263926 DOI: 10.3109/0284186x.2011.652736] [Cited by in Crossref: 73] [Cited by in F6Publishing: 26] [Article Influence: 8.1] [Reference Citation Analysis]
10 Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol. 2010;34:1630-1636. [PMID: 20975341 DOI: 10.1097/pas.0b013e3181f31caa] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
11 Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Beretta L. Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology. 2016;63:864-879. [PMID: 26599259 DOI: 10.1002/hep.28367] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 11.4] [Reference Citation Analysis]
12 Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis: TREATMENT OF IMMUNE TOLERANT HBV. Alimentary Pharmacology & Therapeutics 2007;26:383-91. [DOI: 10.1111/j.1365-2036.2007.03382.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
13 Weir HK, Jim MA, Marrett LD, Fairley T. Cancer in American Indian and Alaska Native young adults (ages 20-44 years): US, 1999-2004. Cancer 2008;113:1153-67. [PMID: 18720386 DOI: 10.1002/cncr.23731] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
14 Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL;  HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493-502. [PMID: 19852963 DOI: 10.1053/j.gastro.2009.10.031] [Cited by in Crossref: 338] [Cited by in F6Publishing: 302] [Article Influence: 28.2] [Reference Citation Analysis]
15 Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA. Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008;12:1139-65. [PMID: 18694380 DOI: 10.1517/14728222.12.9.1139] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 7.8] [Reference Citation Analysis]
16 Zhang W, Sun B. Impact of age on the survival of patients with liver cancer: an analysis of 27,255 patients in the SEER database. Oncotarget 2015;6:633-41. [PMID: 25575810 DOI: 10.18632/oncotarget.2719] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
17 Andres Ibarra R, Abbas R, Kombu RS, Zhang GF, Jacobs G, Lee Z, Brunengraber H, Sanabria JR. Disturbances in the glutathione/ophthalmate redox buffer system in the woodchuck model of hepatitis virus-induced hepatocellular carcinoma. HPB Surg 2011;2011:789323. [PMID: 21941408 DOI: 10.1155/2011/789323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
18 Casadei Gardini A, Marisi G, Scarpi E, Scartozzi M, Faloppi L, Silvestris N, Masi G, Vivaldi C, Brunetti O, Tamberi S. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opin Pharmacother. 2015;16:2719-2725. [PMID: 26513009 DOI: 10.1517/14656566.2015.1102887] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
19 Yao FY, Hirose R, LaBerge JM, Davern TJ 3rd, Bass NM, Kerlan RK Jr, Merriman R, Feng S, Freise CE, Ascher NL, Roberts JP. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005;11:1505-14. [PMID: 16315294 DOI: 10.1002/lt.20526] [Cited by in Crossref: 209] [Cited by in F6Publishing: 186] [Article Influence: 13.9] [Reference Citation Analysis]
20 Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:423-32. [DOI: 10.1038/nrgastro.2009.86] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 6.7] [Reference Citation Analysis]
21 Zhu X, Wu X, Cheng J, Liao H, Di X, Li L, Li R, Zhou Y, Zhang X. Dalbinol, a rotenoid from Amorpha fruticosa L., exerts anti-proliferative activity by facilitating β-catenin degradation in hepatocellular carcinoma cells. Oncotarget 2017;8:47755-66. [PMID: 28548956 DOI: 10.18632/oncotarget.17766] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ahmed KT, Almashhrawi AA, Ibdah JA, Tahan V. Is the 25-year hepatitis C marathon coming to an end to declare victory? World J Hepatol 2017; 9(21): 921-929 [PMID: 28824743 DOI: 10.4254/wjh.v9.i21.921] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
23 Hsu A, Lai CL, Yuen MF. Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. Curr Hepat Rep. 2011;10:106-111. [PMID: 21654908 DOI: 10.1007/s11901-011-0094-] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Portillo P, Yavuz S, Bril F, Cusi K. Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2014;13:159-70. [DOI: 10.1007/s11901-014-0229-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
25 Su WW, Chen CH, Lin HH, Yang SS, Chang TT, Cheng KS, Wu JC, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Lu SN. Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas. Hepatol Int 2009;3:537-43. [PMID: 19669239 DOI: 10.1007/s12072-009-9146-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
26 Lai YH, Shun SC, Hsiao YL, Chiou JF, Wei LL, Tsai JT, Kao CY. Fatigue experiences in hepatocellular carcinoma patients during six weeks of stereotactic radiotherapy. Oncologist 2007;12:221-30. [PMID: 17296818 DOI: 10.1634/theoncologist.12-2-221] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
27 Bishay VL, Maglione K, Khanna R, Lee KM, Fischman AM, Lookstein RA, Kim E. Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy. J Hepatocell Carcinoma 2014;1:187-93. [PMID: 27508187 DOI: 10.2147/JHC.S71602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Tovoli F, Casadei-Gardini A, Benevento F, Piscaglia F. Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019. Dig Liver Dis 2019;51:1067-73. [PMID: 31208929 DOI: 10.1016/j.dld.2019.05.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
29 Wu L, Peng CW, Hou JX, Zhang YH, Chen C, Chen LD, Li Y. Coronin-1C is a novel biomarker for hepatocellular carcinoma invasive progression identified by proteomics analysis and clinical validation. J Exp Clin Cancer Res 2010;29:17. [PMID: 20181269 DOI: 10.1186/1756-9966-29-17] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
30 Cicinnati VR, Zhang X, Yu Z, Ferencik S, Schmitz KJ, Dworacki G, Kaczmarek E, Oldhafer K, Frilling A, Baba HA, Schmid KW, Grosse-wilde H, Broelsch CE, Deleo AB, Gerken G, Beckebaum S. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma. Int J Cancer 2006;119:2851-60. [DOI: 10.1002/ijc.22251] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
31 Bigsby RM, Caperell-Grant A. The role for estrogen receptor-alpha and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis. Carcinogenesis 2011;32:1162-6. [PMID: 21606321 DOI: 10.1093/carcin/bgr094] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
32 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 11.4] [Reference Citation Analysis]
33 Wigham A, Alexander Grant L. Preoperative hepatobiliary imaging: what does the radiologist need to know? Semin Ultrasound CT MR 2013;34:2-17. [PMID: 23395314 DOI: 10.1053/j.sult.2012.11.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
34 Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:123-133. [PMID: 22212946 DOI: 10.1159/000333275] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
35 Li Z, Zhang H, Yang J, Hao T, Li S. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma. Cell Biol Int 2012;36:427-32. [PMID: 21864295 DOI: 10.1042/CBI20100851] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
36 Huang R, Yan G, Sun H, Zhang J, Song D, Kong R, Yan P, Hu P, Xie A, Wang S, Zhuang J, Yin H, Meng T, Huang Z. Identification of prognostic and metastasis-related alternative splicing signatures in hepatocellular carcinoma. Biosci Rep 2020;40:BSR20201001. [PMID: 32627826 DOI: 10.1042/BSR20201001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 Kim D, Kim J, Kwak CH, Heo NS, Oh SY, Lee H, Lee G, Vilian AE, Han Y, Kim W, Kim G, Kwon S, Huh YS. Rapid and label-free bioanalytical method of alpha fetoprotein detection using LSPR chip. Journal of Crystal Growth 2017;469:131-5. [DOI: 10.1016/j.jcrysgro.2016.09.066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
38 Song IH. Molecular targeting for treatment of advanced hepatocellular carcinoma. Korean J Hepatol 2009;15:299. [DOI: 10.3350/kjhep.2009.15.3.299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
39 Seinstra BA, Defreyne L, Lambert B, Lam MG, Verkooijen HM, van Erpecum KJ, van Hoek B, van Erkel AR, Coenraad MJ, Al Younis I. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials. 2012;13:144. [PMID: 22913492 DOI: 10.1186/1745-6215-13-144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
40 Goessling W. Deciphering Hepatocellular Carcinoma: From Bench to Bedside and Back. Gastroenterology 2009;137:786-8. [DOI: 10.1053/j.gastro.2009.07.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
41 Goh GB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol. 2015;29:919-928. [PMID: 26651253 DOI: 10.1016/j.bpg.2015.09.007] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 12.3] [Reference Citation Analysis]
42 Vivekanandan P, Singh OV. High-dimensional biology to comprehend hepatocellular carcinoma. Expert Rev Proteomics. 2008;5:45-60. [PMID: 18282123 DOI: 10.1586/14789450.5.1.45] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
43 Paprottka PM, Jakobs TF, Reiser MF, Hoffmann RT. Practical vascular anatomy in the preparation of radioembolization. Cardiovasc Intervent Radiol. 2012;35:454-462. [PMID: 21567273 DOI: 10.1007/s00270-011-0169-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
44 Wang P, Wang C, Li H, Shi B, Wang J, Zhong L. Impact of age on the prognosis after liver transplantation for patients with hepatocellular carcinoma: a single-center experience. Onco Targets Ther 2015;8:3775-81. [PMID: 26719705 DOI: 10.2147/OTT.S93939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
45 Coulouarn C, Factor VM, Conner EA, Thorgeirsson SS. Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. Carcinogenesis. 2011;32:1434-1440. [PMID: 21771728 DOI: 10.1093/carcin/bgr133] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
46 Shih YL, Hsieh CB, Lai HC, Yan MD, Hsieh TY, Chao YC, Lin YW. SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int J Cancer. 2007;121:1028-1035. [PMID: 17443492 DOI: 10.1002/ijc.22750] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 4.6] [Reference Citation Analysis]
47 Zhao Y, Zhang Y, Vazirinejad Mehdiabad M, Zhou K, Chen Y, Li L, Guo J, Xu C. Enhanced anti-tumor effect of liposomal Fasudil on hepatocellular carcinoma in vitro and in vivo. PLoS One 2019;14:e0223232. [PMID: 31581236 DOI: 10.1371/journal.pone.0223232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, Quan D, McAllister V, Ghent C, Levstik M. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl. 2007;13:543-551. [PMID: 17394152 DOI: 10.1002/lt.21078] [Cited by in Crossref: 110] [Cited by in F6Publishing: 108] [Article Influence: 7.9] [Reference Citation Analysis]
49 Lodewyks C, Rodriguez JF, Yan J, Lerner B, Sun D, Rempel JD, Uhanova J, Labine M, Minuk GY. Activation of β-adrenergic receptors increases the in vitro migration of malignant hepatocytes. Hepatol Res 2011;41:1000-8. [PMID: 21951873 DOI: 10.1111/j.1872-034X.2011.00854.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
50 Bishayee A, Dhir N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: Inhibition of cell proliferation and induction of apoptosis. Chemico-Biological Interactions 2009;179:131-44. [DOI: 10.1016/j.cbi.2008.11.015] [Cited by in Crossref: 110] [Cited by in F6Publishing: 102] [Article Influence: 9.2] [Reference Citation Analysis]
51 van den Bos IC, Hussain SM, de Man RA, Zondervan PE, Ijzermans JN, Krestin GP. Primary hepatocellular lesions: imaging findings on state-of-the-art magnetic resonance imaging, with pathologic correlation. Curr Probl Diagn Radiol. 2008;37:104-114. [PMID: 18436110 DOI: 10.1067/j.cpradiol.2007.07.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
52 Boissan M, Lacombe ML. Nm23/NDP kinases in hepatocellular carcinoma. J Bioenerg Biomembr. 2006;38:169-175. [PMID: 16944304 DOI: 10.1007/s10863-006-9031-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
53 Lee JS. Genomic profiling of liver cancer. Genomics Inform 2013;11:180-5. [PMID: 24465228 DOI: 10.5808/GI.2013.11.4.180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
54 Jiang Y, Yim SH, Xu HD, Jung SH, Yang SY, Hu HJ, Jung CK, Chung YJ. A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma. World J Gastroenterol 2011; 17(4): 470-477 [PMID: 21274376 DOI: 10.3748/wjg.v17.i4.470] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
55 Fassio E. Hepatitis C and hepatocellular carcinoma. Annals of Hepatology 2010;9:S119-22. [DOI: 10.1016/s1665-2681(19)31736-3] [Cited by in Crossref: 26] [Article Influence: 2.4] [Reference Citation Analysis]
56 Owen WE, Roberts RF, Roberts WL. Performance characteristics of the LiBASys® des-gamma-carboxy prothrombin assay. Clinica Chimica Acta 2008;389:183-5. [DOI: 10.1016/j.cca.2007.11.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
57 De Giorgio M, Vezzoli S, Cohen E, Armellini E, Lucà MG, Verga G, Pinelli D, Nani R, Valsecchi MG, Antolini L. Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transpl. 2010;16:503-512. [PMID: 20373461 DOI: 10.1002/lt.22039] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
58 Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, Serraino D, Franceschi S, Talamini R. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol. 2009;20:353-357. [PMID: 18723550 DOI: 10.1093/annonc/mdn565] [Cited by in Crossref: 120] [Cited by in F6Publishing: 123] [Article Influence: 9.2] [Reference Citation Analysis]
59 Anaparthy R, Talwalkar JA, Yin M, Roberts LR, Fidler JL, Ehman RL. Liver stiffness measurement by magnetic resonance elastography is not associated with developing hepatocellular carcinoma in subjects with compensated cirrhosis. Aliment Pharmacol Ther 2011;34:83-91. [PMID: 21535445 DOI: 10.1111/j.1365-2036.2011.04673.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
60 Ho JC, Ip YC, Cheung ST, Lee YT, Chan KF, Wong SY, Fan ST. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 2008;47:1524-32. [PMID: 18393387 DOI: 10.1002/hep.22191] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 6.5] [Reference Citation Analysis]
61 Buendia MA. Tumor suppressors in hepatocellular carcinoma: many are called, but few are chosen. J Hepatol 2007;46:546-8. [PMID: 17313992 DOI: 10.1016/j.jhep.2007.01.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
62 Cotrim HP, Oliveira CP, Coelho HS, Alvares-da-Silva MR, Nabuco L, Parise ER, Ivantes C, Martinelli AL, Galizzi-Filho J, Carrilho FJ. Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey. Clinics (Sao Paulo). 2016;71:281-284. [PMID: 27276398 DOI: 10.6061/clinics/2016(05)07] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
63 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.2165/00066982-200408040-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
64 Kim J, Hong SJ, Park JY, Park JH, Yu Y, Park SY, Lim EK, Choi KY, Lee EK, Paik SS, Lee KG, Wang HJ, Do I, Joh J, Kim DS; on behalf of the Korea Cancer Biomarker Consortium. Epithelial-mesenchymal transition gene signature to predict clinical outcome of hepatocellular carcinoma. Cancer Science 2010;101:1521-8. [DOI: 10.1111/j.1349-7006.2010.01536.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
65 Bugianesi E. Review article: steatosis, the metabolic syndrome and cancer. Aliment Pharmacol Ther. 2005;22 Suppl 2:40-43. [PMID: 16225471 DOI: 10.1111/j.1365-2036.2005.02594.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
66 Qian H, Yang Y, Wang X. Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy. Eur J Pharm Sci. 2011;43:125-131. [PMID: 21514382 DOI: 10.1016/j.ejps.2011.04.002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 6.1] [Reference Citation Analysis]
67 Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology. 2008;47:2059-2067. [PMID: 18506891 DOI: 10.1002/hep.22283] [Cited by in Crossref: 227] [Cited by in F6Publishing: 227] [Article Influence: 17.5] [Reference Citation Analysis]
68 Nakagawa T, Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Matsushita M, Todo S. Pulmonary resection for metastases from hepatocellular carcinoma: factors influencing prognosis. J Thorac Cardiovasc Surg. 2006;131:1248-1254. [PMID: 16733153 DOI: 10.1016/j.jtcvs.2006.02.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
69 Dayoub R, Wagner H, Bataille F, Stöltzing O, Spruss T, Buechler C, Schlitt HJ, Weiss TS. Liver regeneration associated protein (ALR) exhibits antimetastatic potential in hepatocellular carcinoma. Mol Med 2011;17:221-8. [PMID: 21152698 DOI: 10.2119/molmed.2010.00117] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
70 Addario L, Tritto G, Cavaglià E, Amodio F, Giannelli E, Di Costanzo GG. Preserved liver function, portal thrombosis and absence of oesophageal varices are risk factors for metastasis of hepatocellular carcinoma. Dig Liver Dis. 2011;43:319-324. [PMID: 20952262 DOI: 10.1016/j.dld.2010.09.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
71 Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A, Thorgeirsson SS. Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology. 2010;51:1401-1409. [PMID: 20054870 DOI: 10.1002/hep.23488] [Cited by in Crossref: 95] [Cited by in F6Publishing: 99] [Article Influence: 8.6] [Reference Citation Analysis]
72 Koniaris LG, Levi DM, Pedroso FE, Franceschi D, Tzakis AG, Santamaria-Barria JA, Tang J, Anderson M, Misra S, Solomon NL. Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma? Ann Surg. 2011;254:527-537; discussion 537-538. [PMID: 21865950 DOI: 10.1097/sla.0b013e3182ca66f] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Wu C, Chen P, Qian JJ, Jin SJ, Yao J, Wang XD, Bai DS, Jiang GQ. Effect of marital status on the survival of patients with hepatocellular carcinoma treated with surgical resection: an analysis of 13,408 patients in the surveillance, epidemiology, and end results (SEER) database. Oncotarget 2016;7:79442-52. [PMID: 27769053 DOI: 10.18632/oncotarget.12722] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
74 Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191-199. [PMID: 25142309 DOI: 10.1002/hep.27388] [Cited by in Crossref: 311] [Cited by in F6Publishing: 307] [Article Influence: 44.4] [Reference Citation Analysis]
75 Raoul J. Natural History of Hepatocellular Carcinoma and Current Treatment Options. Seminars in Nuclear Medicine 2008;38:S13-8. [DOI: 10.1053/j.semnuclmed.2007.10.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
76 Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology. 2012;143:974-985.e14. [PMID: 22863764 DOI: 10.1053/j.gastro.2012.05.054] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 10.0] [Reference Citation Analysis]
77 Wu J, Song L, Zhao DY, Guo B, Liu J. Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2014; 20(31): 10960-10968 [PMID: 25152600 DOI: 10.3748/wjg.v20.i31.10960] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
78 Borentain P, Gérolami V, Ananian P, Garcia S, Noundou A, Botta-Fridlund D, Le Treut YP, Bergé-Lefranc JL, Gérolami R. DNA-repair and carcinogen-metabolising enzymes genetic polymorphisms as an independent risk factor for hepatocellular carcinoma in Caucasian liver-transplanted patients. Eur J Cancer. 2007;43:2479-2486. [PMID: 17870518 DOI: 10.1016/j.ejca.2007.08.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
79 Herman P, Lopes FDLM, Kruger JAP, Fonseca GM, Jeismann VB, Coelho FF. IS RESECTION OF HEPATOCELLULAR CARCINOMA IN THE ERA OF LIVER TRANSPLANTATION WORTHWILE? A single center experience. Arq Gastroenterol 2016;53:169-74. [DOI: 10.1590/s0004-28032016000300009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
80 Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 2010;52:594-604. [PMID: 20185200 DOI: 10.1016/j.jhep.2009.10.033] [Cited by in Crossref: 259] [Cited by in F6Publishing: 263] [Article Influence: 23.5] [Reference Citation Analysis]
81 Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol. 2009;25:186-194. [PMID: 19387255 DOI: 10.1097/mog.0b013e32832962a1] [Cited by in Crossref: 101] [Cited by in F6Publishing: 51] [Article Influence: 8.4] [Reference Citation Analysis]
82 Seren S, Mutchnick M, Hutchinson D, Harmanci O, Bayraktar Y, Mutchnick S, Sahin K, Kucuk O. Potential role of lycopene in the treatment of hepatitis C and prevention of hepatocellular carcinoma. Nutr Cancer 2008;60:729-35. [PMID: 19005972 DOI: 10.1080/01635580802419772] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
83 Mazzocca A, Dituri F, Lupo L, Quaranta M, Antonaci S, Giannelli G. Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. Hepatology. 2011;54:920-930. [PMID: 21674557 DOI: 10.1002/hep.24485] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 8.5] [Reference Citation Analysis]
84 Hiatt T, Trotter JF, Kam I. Hepatocellular carcinoma in a noncirrhotic patient with hereditary hemochromatosis. Am J Med Sci 2007;334:228-30. [PMID: 17873542 DOI: 10.1097/MAJ.0b013e3181425209] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
85 Soto-Salgado M, Suárez E, Ortiz AP, Adrovet S, Marrero E, Meléndez M, Colón HM, Albizu C, Del C Santos M, Torres E, Pérez CM. Knowledge of viral hepatitis among Puerto Rican adults: implications for prevention. J Community Health 2011;36:565-73. [PMID: 21125319 DOI: 10.1007/s10900-010-9342-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
86 Harvin JA, Van Buren G, Tsao K, Cen P, Ko TC, Wray CJ. Hepatocellular carcinoma survival in uninsured and underinsured patients. J Surg Res 2011;166:189-93. [PMID: 20638680 DOI: 10.1016/j.jss.2010.04.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
87 Vashist YK, Tiffon C, Stoupis C, Redaelli CA. Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. World J Gastroenterol 2006; 12(42): 6771-6778 [PMID: 17106924 DOI: 10.3748/wjg.v12.i42.6771] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
88 Phipps M, Livanos A, Guo A, Pomenti S, Yeh J, Dakhoul L, Burney H, Kettler C, Liu H, Miller E, Gawrieh S, deLemos A, Scanga A, Chalasani N, Wattacheril J. Gender Matters: Characteristics of Hepatocellular Carcinoma in Women From a Large, Multicenter Study in the United States. Am J Gastroenterol 2020;115:1486-95. [PMID: 32453046 DOI: 10.14309/ajg.0000000000000643] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
89 Miller JC, Hahn PF, Chung RT, Thrall JH, Lee SI. Screening for hepatocellular carcinoma in cirrhotic patients. J Am Coll Radiol. 2008;5:1012-1014. [PMID: 18755444 DOI: 10.1016/j.jacr.2008.01.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
90 Loomba R, Yang HI, Su J, Brenner D, Iloeje U, Chen CJ. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol 2010; 8: 891-898, 898.e1-898. e2. [PMID: 20621202 DOI: 10.1016/j.cgh.2010.06.027] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
91 Seitz HK, Cho CH. Contribution of alcohol and tobacco use in gastrointestinal cancer development. Methods Mol Biol 2009;472:217-41. [PMID: 19107435 DOI: 10.1007/978-1-60327-492-0_9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
92 Banerjee A, Ray RB, Ray R. Oncogenic potential of hepatitis C virus proteins. Viruses. 2010;2:2108-2133. [PMID: 21994721 DOI: 10.3390/v2092108] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 6.9] [Reference Citation Analysis]
93 Chen X, Wang H, Xie W, Liang R, Wei Z, Zhi L, Zhang X, Hao B, Zhong S, Zhou G, Zhang L, Gao X, Zhu Y, He F. Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a high-risk region of China. Pharmacogenet Genomics 2006;16:219-27. [PMID: 16495781 DOI: 10.1097/01.fpc.0000194424.20393.c6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.1] [Reference Citation Analysis]
94 Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. Hepatocellular carcinoma surveillance: a national survey of current practices in the USA. Dig Dis Sci 2014;59:3073-7. [PMID: 25027206 DOI: 10.1007/s10620-014-3256-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
95 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 94] [Article Influence: 2.4] [Reference Citation Analysis]
96 Tu QV, Okoli AS, Kovach Z, Mendz GL. Hepatocellular carcinoma: prevalence and molecular pathogenesis of Helicobacter spp. Future Microbiol. 2009;4:1283-1301. [PMID: 19995189 DOI: 10.2217/fmb.09.90] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
97 Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;CD001199. [PMID: 19160192 DOI: 10.1002/14651858.cd001199] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
98 Duffy JP, Hiatt JR, Busuttil RW. Surgical resection of hepatocellular carcinoma. Cancer J. 2008;14:100-110. [PMID: 18391615 DOI: 10.1097/ppo.0b013e31816a5c1f] [Cited by in Crossref: 39] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
99 Fransvea E, Mazzocca A, Santamato A, Azzariti A, Antonaci S, Giannelli G. Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study. Cancer Chemother Pharmacol. 2011;68:79-86. [PMID: 20844878 DOI: 10.1007/s00280-010-1459-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
100 Huang J, Zhang YL, Teng XM, Lin Y, Zheng DL, Yang PY, Han ZG. Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC Cancer 2007;7:126. [PMID: 17626620 DOI: 10.1186/1471-2407-7-126] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
101 Bugianesi E, Vanni E, Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep. 2007;7:175-180. [PMID: 17547834 DOI: 10.1007/s11892-007-0029-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
102 Siegel A. Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors. Gastroenterology 2008;135:733-5. [PMID: 18692053 DOI: 10.1053/j.gastro.2008.07.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
103 Motosugi U, Ichikawa T, Koshiishi T, Sano K, Morisaka H, Ichikawa S, Enomoto N, Matsuda M, Fujii H, Araki T. Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: a preliminary case-control study. Eur Radiol 2013;23:156-62. [PMID: 22814828 DOI: 10.1007/s00330-012-2571-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
104 Nguyen VT, Razali K, Amin J, Law MG, Dore GJ. Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries. J Gastroenterol Hepatol 2008;23:922-9. [PMID: 17608637 DOI: 10.1111/j.1440-1746.2007.05065.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
105 Samuel ST, Martinez AD, Chen Y, Markatou M, Talal AH. Hepatitis C virus knowledge improves hepatitis C virus screening practices among primary care physicians. World J Hepatol 2018; 10(2): 319-328 [PMID: 29527267 DOI: 10.4254/wjh.v10.i2.319] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
106 Sakisaka M, Haruta M, Komohara Y, Umemoto S, Matsumura K, Ikeda T, Takeya M, Inomata Y, Nishimura Y, Senju S. Therapy of primary and metastatic liver cancer by human iPS cell-derived myeloid cells producing interferon-β. J Hepatobiliary Pancreat Sci 2017;24:109-19. [PMID: 28008721 DOI: 10.1002/jhbp.422] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
107 Quick AM, Bloomston M, Kim EY, Hall NC, Mayr NA. Complete response to radiation therapy of orbital metastasis from hepatocellular carcinoma. World J Gastroenterol 2009; 15(47): 6000-6003 [PMID: 20014466 DOI: 10.3748/wjg.15.6000] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
108 Lai JP, Thompson JR, Sandhu DS, Roberts LR. Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. Future Oncol. 2008;4:803-814. [PMID: 19086847 DOI: 10.2217/14796694.4.6.803] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
109 Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006;44:1675-1684. [PMID: 17133499 DOI: 10.1002/hep.21440] [Cited by in Crossref: 117] [Cited by in F6Publishing: 96] [Article Influence: 8.4] [Reference Citation Analysis]
110 Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology. 2005;129:1375-1383. [PMID: 16285938 DOI: 10.1053/j.gastro.2005.09.055] [Cited by in Crossref: 184] [Cited by in F6Publishing: 174] [Article Influence: 12.3] [Reference Citation Analysis]
111 Davis GL, Roberts WL. The Healthcare Burden Imposed by Liver Disease in Aging Baby Boomers. Curr Gastroenterol Rep 2010;12:1-6. [DOI: 10.1007/s11894-009-0087-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
112 O'Leary JG, Yachimski PS, Friedman LS. Surgery in the patient with liver disease. Clin Liver Dis. 2009;13:211-231. [PMID: 19442915 DOI: 10.1016/j.cld.2009.02.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
113 Tencate V, Sainz B Jr, Cotler SJ, Uprichard SL. Potential treatment options and future research to increase hepatitis C virus treatment response rate. Hepat Med. 2010;2010:125-145. [PMID: 21331152 DOI: 10.2147/hmer.s7193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
114 Rawla P, Thandra KC, Vellipuram A, Ali CDM. Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature. Contemp Oncol (Pozn) 2018;22:209-14. [PMID: 30783383 DOI: 10.5114/wo.2018.82641] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Vacca M, Murzilli S, Salvatore L, Di Tullio G, D'Orazio A, Lo Sasso G, Graziano G, Pinzani M, Chieppa M, Mariani-Costantini R, Palasciano G, Moschetta A. Neuron-derived orphan receptor 1 promotes proliferation of quiescent hepatocytes. Gastroenterology 2013;144:1518-1529.e3. [PMID: 23462179 DOI: 10.1053/j.gastro.2013.02.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
116 Lee G, Jeong YS, Kim DW, Kwak MJ, Koh J, Joo EW, Lee JS, Kah S, Sim YE, Yim SY. Clinical significance of APOB inactivation in hepatocellular carcinoma. Exp Mol Med 2018;50:1-12. [PMID: 30429453 DOI: 10.1038/s12276-018-0174-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
117 Pérez V. Viral hepatitis: historical perspectives from the 20th to the 21st century. Arch Med Res. 2007;38:593-605. [PMID: 17613350 DOI: 10.1016/j.arcmed.2006.09.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
118 Guerrero-Preston R, Siegel A, Renz J, Vlahov D, Neugut A. HCV infection and cryptogenic cirrhosis are risk factors for hepatocellular carcinoma among Latinos in New York City. J Community Health 2009;34:500-5. [PMID: 19705261 DOI: 10.1007/s10900-009-9184-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
119 Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? World J Gastroenterol 2013; 19(47): 8808-8821 [PMID: 24379604 DOI: 10.3748/wjg.v19.i47.8808] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
120 Jiang P, Cao J, Bai WH. Lentivirus-Mediated siRNA Targeting ER-α Inhibits Tumorigenesis and Induces Apoptosis in Hepatocarcinoma Cells. Biomed Res Int 2015;2015:490681. [PMID: 26413526 DOI: 10.1155/2015/490681] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
121 Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 938-945, 945.e1-945. e4. [PMID: 17509946 DOI: 10.1016/j.cgh.2007.02.039] [Cited by in Crossref: 140] [Cited by in F6Publishing: 127] [Article Influence: 10.0] [Reference Citation Analysis]
122 Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2015;1:CD006745. [PMID: 25620061 DOI: 10.1002/14651858.CD006745.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
123 Do AL, Wong CR, Nguyen LH, Nguyen VG, Trinh H, Nguyen MH. Hepatocellular Carcinoma Incidence in Noncirrhotic Patients With Chronic Hepatitis B and Patients With Cirrhosis of All Etiologies. Journal of Clinical Gastroenterology 2014;48:644-9. [DOI: 10.1097/mcg.0000000000000015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
124 Haile RW, John EM, Levine AJ, Cortessis VK, Unger JB, Gonzales M, Ziv E, Thompson P, Spruijt-Metz D, Tucker KL, Bernstein JL, Rohan TE, Ho GY, Bondy ML, Martinez ME, Cook L, Stern MC, Correa MC, Wright J, Schwartz SJ, Baezconde-Garbanati L, Blinder V, Miranda P, Hayes R, Friedman-Jiménez G, Monroe KR, Haiman CA, Henderson BE, Thomas DC, Boffetta P. A review of cancer in U.S. Hispanic populations. Cancer Prev Res (Phila) 2012;5:150-63. [PMID: 22307564 DOI: 10.1158/1940-6207.CAPR-11-0447] [Cited by in Crossref: 66] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
125 Ji J, Tang J, Deng L, Xie Y, Jiang R, Li G, Sun B. LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway. Oncotarget. 2015;6:42813-42824. [PMID: 26540343 DOI: 10.18632/oncotarget.5970] [Cited by in Crossref: 88] [Cited by in F6Publishing: 96] [Article Influence: 17.6] [Reference Citation Analysis]
126 Woo HG, Park ES, Thorgeirsson SS, Kim YJ. Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog 2011;50:235-43. [PMID: 21465573 DOI: 10.1002/mc.20691] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
127 Piscaglia F, Leoni S, Cabibbo G, Borghi A, Imbriaco G, Golfieri R, Bolondi L. Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. Digestive and Liver Disease 2010;42:729-34. [DOI: 10.1016/j.dld.2010.03.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
128 Chen Q, Tang H, Zha Z, Yin H, Wang Y, Wang Y, Li H, Yue L. β-d-glucan from Antrodia Camphorata ameliorates LPS-induced inflammation and ROS production in human hepatocytes. International Journal of Biological Macromolecules 2017;104:768-77. [DOI: 10.1016/j.ijbiomac.2017.05.191] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
129 Nabavi SF, Daglia M, Moghaddam AH, Habtemariam S, Nabavi SM. Curcumin and Liver Disease: from Chemistry to Medicine: Curcumin and liver disease…. Comprehensive Reviews in Food Science and Food Safety 2014;13:62-77. [DOI: 10.1111/1541-4337.12047] [Cited by in Crossref: 97] [Cited by in F6Publishing: 59] [Article Influence: 12.1] [Reference Citation Analysis]
130 Jim MA, Perdue DG, Richardson LC, Espey DK, Redd JT, Martin HJ, Kwong SL, Kelly JJ, Henderson JA, Ahmed F. Primary liver cancer incidence among American Indians and Alaska Natives, US, 1999-2004. Cancer. 2008;113:1244-1255. [PMID: 18720380 DOI: 10.1002/cncr.23728] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
131 Giakoustidis AE, Giakoustidis DE. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. Immunotherapy 2017;9:197-206. [PMID: 28128716 DOI: 10.2217/imt-2016-0110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 2012;107:64-74. [PMID: 21931376 DOI: 10.1038/ajg.2011.312] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 7.4] [Reference Citation Analysis]
133 Mondal A. A novel extraction of trichosanthin from Trichosanthes kirilowii roots using three-phase partitioning and its in vitro anticancer activity. Pharmaceutical Biology 2014;52:677-80. [DOI: 10.3109/13880209.2013.864684] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
134 Szepeshazi K, Schally AV, Treszl A, Seitz S, Halmos G. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin. Anti-Cancer Drugs 2008;19:349-58. [DOI: 10.1097/cad.0b013e3282f9adce] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
135 Jeng LB, Velmurugan BK, Hsu HH, Wen SY, Shen CY, Lin CH, Lin YM, Chen RJ, Kuo WW, Huang CY. Fenofibrate induced PPAR alpha expression was attenuated by oestrogen receptor alpha overexpression in Hep3B cells. Environ Toxicol 2018;33:234-47. [PMID: 29134746 DOI: 10.1002/tox.22511] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
136 Jiao J, González Á, Stevenson HL, Gagea M, Sugimoto H, Kalluri R, Beretta L. Depletion of S100A4+ stromal cells does not prevent HCC development but reduces the stem cell-like phenotype of the tumors. Exp Mol Med 2018;50:e422. [PMID: 29303514 DOI: 10.1038/emm.2017.175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
137 Lu N, Khachatoorian R, French SW. Quercetin: bioflavonoids as part of interferon-free hepatitis C therapy? Expert Rev Anti Infect Ther 2012;10:619-21. [PMID: 22734951 DOI: 10.1586/eri.12.52] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
138 Amann T, Hellerbrand C. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 2009;13:1411-27. [PMID: 19874261 DOI: 10.1517/14728220903307509] [Cited by in Crossref: 118] [Cited by in F6Publishing: 118] [Article Influence: 10.7] [Reference Citation Analysis]
139 Chignard N, Shang S, Wang H, Marrero J, Bréchot C, Hanash S, Beretta L. Cleavage of Endoplasmic Reticulum Proteins in Hepatocellular Carcinoma: Detection of Generated Fragments in Patient Sera. Gastroenterology 2006;130:2010-22. [DOI: 10.1053/j.gastro.2006.02.058] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
140 Wickline ED, Du Y, Stolz DB, Kahn M, Monga SP. γ-Catenin at adherens junctions: mechanism and biologic implications in hepatocellular cancer after β-catenin knockdown. Neoplasia 2013;15:421-34. [PMID: 23555187 DOI: 10.1593/neo.122098] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
141 Kikuchi L, Oliveira CP, Alvares-da-Silva MR, Tani CM, Diniz MA, Stefano JT, Chagas AL, Alencar RS, Vezozzo DC, Santos GR, Campos PB, Alves VA, Ratziu V, Carrilho FJ. Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System. Am J Clin Oncol. 2016;39:428-432. [PMID: 25268068 DOI: 10.1097/coc.0000000000000134] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
142 Naito S, Imamura H, Tukada A, Matsuyama Y, Yoshimoto J, Sugo H, Ishizaki Y, Kawasaki S. Postoperative recurrence pattern and prognosis of patients with hepatocellular carcinoma, with particular reference to the hepatitis viral infection status. Liver Int. 2014;34:802-813. [PMID: 24350618 DOI: 10.1111/liv.12447] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
143 Krishnan G, Subramaniyan J, Chengalvarayan Subramani P, Muralidharan B, Thiruvengadam D. Hesperetin conjugated PEGylated gold nanoparticles exploring the potential role in anti-inflammation and anti-proliferation during diethylnitrosamine-induced hepatocarcinogenesis in rats. Asian J Pharm Sci 2017;12:442-55. [PMID: 32104357 DOI: 10.1016/j.ajps.2017.04.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
144 Hodges KB, Cummings OW, Saxena R, Wang M, Zhang S, Lopez-Beltran A, Montironi R, Nour H, Cheng L. Clonal origin of multifocal hepatocellular carcinoma. Cancer. 2010;116:4078-4085. [PMID: 20564142 DOI: 10.1002/cncr.25258] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
145 Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol 2014; 20(20): 5951-5961 [PMID: 24876718 DOI: 10.3748/wjg.v20.i20.5951] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
146 Abou-Alfa GK, Venook AP. The impact of new data in the treatment of advanced hepatocellular carcinoma. Curr Oncol Rep. 2008;10:199-205. [PMID: 18765149 DOI: 10.1007/s11912-008-0031-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
147 Jin YJ, Lee JW, Choi YJ, Chung HJ, Kim YS, Lee KY, Ahn SI, Shin WY, Cho SG, Jeon YS. Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. J Gastrointest Surg. 2014;18:555-561. [PMID: 24420729 DOI: 10.1007/s11605-013-2440-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
148 Shen H, Agarwal D, Qi R, Chalasani N, Liangpunsakul S, Lumeng L, Yoo H, Kwo P. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment Pharmacol Ther. 2007;26:393-400. [PMID: 17635374 DOI: 10.1111/j.1365-2036.2007.03395.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
149 Liu S, Guo W, Shi J, Li N, Yu X, Xue J, Fu X, Chu K, Lu C, Zhao J. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol. 2012;56:389-396. [PMID: 21888875 DOI: 10.1016/j.jhep.2011.08.008] [Cited by in Crossref: 109] [Cited by in F6Publishing: 108] [Article Influence: 10.9] [Reference Citation Analysis]
150 Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer. 2010;10:475. [PMID: 20813065 DOI: 10.1186/1471-2407-10-475] [Cited by in Crossref: 164] [Cited by in F6Publishing: 157] [Article Influence: 14.9] [Reference Citation Analysis]
151 Daniels MJ, Jiang J, Varghese T. Ultrasound simulation of real-time temperature estimation during radiofrequency ablation using finite element models. Ultrasonics 2008;48:40-55. [PMID: 18082236 DOI: 10.1016/j.ultras.2007.10.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
152 McGivern DR, Lemon SM. Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol. 2009;4:399-415. [PMID: 18928409 DOI: 10.1146/annurev.pathol.4.110807.092202] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
153 Elsayes KM, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, Mitchell DG, Do RK, Fowler KJ, Chernyak V, Sirlin CB. Liver Imaging Reporting and Data System: an expert consensus statement.J Hepatocell Carcinoma. 2017;4:29-39. [PMID: 28255543 DOI: 10.2147/JHC.S125396] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
154 Lee CH, Brubaker LM, Gerber DA, Ku YM, Kim YH, Shin SS, Semelka RC. MRI findings of recurrent hepatocellular carcinoma after liver transplantation: preliminary results. J Magn Reson Imaging. 2011;33:1399-1405. [PMID: 21591009 DOI: 10.1002/jmri.22326] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
155 Wong R, Corley DA. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med. 2008;121:525-531. [PMID: 18501235 DOI: 10.1016/j.amjmed.2008.03.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
156 Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M, Gordon SC, Kwo P, Rockstroh JK, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Res 2013;99:214-20. [PMID: 23747481 DOI: 10.1016/j.antiviral.2013.05.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
157 Kalaitzakis E, Gunnarsdottir SA, Josefsson A, Björnsson E. Increased Risk for Malignant Neoplasms Among Patients With Cirrhosis. Clinical Gastroenterology and Hepatology 2011;9:168-74. [DOI: 10.1016/j.cgh.2010.10.014] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
158 Agni RM. Diagnostic histopathology of hepatocellular carcinoma: A case-based review. Semin Diagn Pathol. 2017;34:126-137. [PMID: 28143798 DOI: 10.1053/j.semdp.2016.12.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
159 Pleguezuelo M, Lopez-Sanchez LM, Rodriguez-Ariza A, Montero JL, Briceno J, Ciria R, Muntane J, Mata ML. Proteomic analysis for developing new biomarkers of hepatocellular carcinoma. World J Hepatol 2010; 2(3): 127-135 [PMID: 21160983 DOI: 10.4254/wjh.v2.i3.127] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
160 Obeng-Adjei N, Hutnick NA, Yan J, Chu JS, Myles DJ, Morrow MP, Sardesai NY, Weiner DB. DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques. Cancer Gene Ther. 2013;20:652-662. [PMID: 24310062 DOI: 10.1038/cgt.2013.65] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
161 O'Leary JG, Davis GL. Hepatitis C virus replication and potential targets for direct-acting agents. Therap Adv Gastroenterol 2010;3:43-53. [PMID: 21180589 DOI: 10.1177/1756283X09353353] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
162 Tseng CH. Type 2 diabetes, smoking, insulin use, and mortality from hepatocellular carcinoma: a 12-year follow-up of a national cohort in Taiwan. Hepatol Int. 2013;7:693-702. [PMID: 26201803 DOI: 10.1007/s12072-012-9405-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
163 Lin YW, Shih YL, Lien GS, Suk FM, Hsieh CB, Yan MD. Promoter methylation of SFRP3 is frequent in hepatocellular carcinoma. Dis Markers 2014;2014:351863. [PMID: 24591760 DOI: 10.1155/2014/351863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
164 Lee JJ, Kim PTW, Fischer S, Fung S, Gallinger S, Mcgilvray I, Moulton C, Wei AC, Greig PD, Cleary SP. Impact of Viral Hepatitis on Outcomes after Liver Resection for Hepatocellular Carcinoma: Results from a North American Center. Ann Surg Oncol 2014;21:2708-16. [DOI: 10.1245/s10434-014-3609-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
165 Yao FY. Liver transplantation for hepatocellular carcinoma: The hepatitis C quandary. Liver Transpl 2007;13:783-5. [DOI: 10.1002/lt.21062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
166 Ai J, Huang H, Lv X, Tang Z, Chen M, Chen T, Duan W, Sun H, Li Q, Tan R, Liu Y, Duan J, Yang Y, Wei Y, Li Y, Zhou Q. FLNA and PGK1 are two potential markers for progression in hepatocellular carcinoma. Cell Physiol Biochem 2011;27:207-16. [PMID: 21471709 DOI: 10.1159/000327946] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 5.9] [Reference Citation Analysis]
167 Hennig M, Yip-Schneider MT, Klein P, Wentz S, Matos JM, Doyle C, Choi J, Wu H, O'Mara A, Menze A, Noble S, McKillop IH, Schmidt CM. Ethanol-TGFalpha-MEK signaling promotes growth of human hepatocellular carcinoma. J Surg Res 2009;154:187-95. [PMID: 19321179 DOI: 10.1016/j.jss.2008.11.836] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
168 Bansal S, Berk M, Alkhouri N, Partrick DA, Fung JJ, Feldstein A. Stearoyl-CoA desaturase plays an important role in proliferation and chemoresistance in human hepatocellular carcinoma. J Surg Res 2014;186:29-38. [PMID: 24135379 DOI: 10.1016/j.jss.2013.07.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
169 Yeh CT, So M, Ng J, Yang HW, Chang ML, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC. Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology. 2010;52:1922-1933. [PMID: 20814897 DOI: 10.1002/hep.23898] [Cited by in Crossref: 57] [Cited by in F6Publishing: 67] [Article Influence: 5.2] [Reference Citation Analysis]
170 Hester D, Golabi P, Paik J, Younossi I, Mishra A, Younossi ZM. Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality. J Clin Gastroenterol 2020;54:459-67. [PMID: 30672817 DOI: 10.1097/MCG.0000000000001172] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
171 Tzeng SY, Higgins LJ, Pomper MG, Green JJ. Student award winner in the Ph.D. category for the 2013 society for biomaterials annual meeting and exposition, april 10-13, 2013, Boston, Massachusetts : biomaterial-mediated cancer-specific DNA delivery to liver cell cultures using synthetic poly(beta-amino ester)s. J Biomed Mater Res A 2013;101:1837-45. [PMID: 23559534 DOI: 10.1002/jbm.a.34616] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
172 El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576. [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061] [Cited by in Crossref: 3516] [Cited by in F6Publishing: 3449] [Article Influence: 251.1] [Reference Citation Analysis]
173 Kikuchi L, Oliveira CP, Carrilho FJ. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Biomed Res Int. 2014;2014:106247. [PMID: 24738043 DOI: 10.1155/2014/106247] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
174 Roth CG, Marzio DH, Guglielmo FF. Contributions of Magnetic Resonance Imaging to Gastroenterological Practice: MRIs for GIs. Dig Dis Sci 2018;63:1102-22. [PMID: 29549474 DOI: 10.1007/s10620-018-4991-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
175 Trinchet JC, Ganne-Carrié N, Nahon P, N'kontchou G, Beaugrand M. Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease. World J Gastroenterol 2007; 13(17): 2455-2460 [PMID: 17552029 DOI: 10.3748/wjg.v13.i17.2455] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
176 Harima Y, Yamasaki T, Hamabe S, Saeki I, Okita K, Terai S, Sakaida I. Effect of a late evening snack using branched-chain amino acid-enriched nutrients in patients undergoing hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatol Res. 2010;40:574-584. [PMID: 20618455 DOI: 10.1111/j.1872-034x.2010.00665.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
177 Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 2008;47:1955-1963. [PMID: 18433021 DOI: 10.1002/hep.22256] [Cited by in Crossref: 497] [Cited by in F6Publishing: 470] [Article Influence: 38.2] [Reference Citation Analysis]
178 Forde KA, Tanapanpanit O, Reddy KR. Hepatitis B and C in African Americans: current status and continued challenges. Clin Gastroenterol Hepatol 2014;12:738-48. [PMID: 23811241 DOI: 10.1016/j.cgh.2013.06.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
179 Padhy AK. Rhenium-188 Lipiodol for the Treatment of Hepatocellular Carcinoma (HCC). In: Baum RP, editor. Therapeutic Nuclear Medicine. Berlin: Springer Berlin Heidelberg; 2014. pp. 393-404. [DOI: 10.1007/174_2013_807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
180 Zhu M, Li L, Lu T, Yoo H, Zhu J, Gopal P, Wang SC, Porembka MR, Rich NE, Kagan S, Odewole M, Renteria V, Waljee AK, Wang T, Singal AG, Yopp AC, Zhu H. Uncovering Biological Factors That Regulate Hepatocellular Carcinoma Growth Using Patient-Derived Xenograft Assays. Hepatology 2020;72:1085-101. [PMID: 31899548 DOI: 10.1002/hep.31096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
181 Lu D, Han C, Wu T. Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/β-catenin signaling axis. Oncogene 2012;31:842-57. [PMID: 21743491 DOI: 10.1038/onc.2011.287] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
182 Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, Yamashiki N, Yoshida H, Kanai F, Kato N. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2008;6:459-464. [PMID: 18387499 DOI: 10.1016/j.cgh.2008.02.012] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 7.8] [Reference Citation Analysis]
183 Marrero CR, Marrero JA. Viral Hepatitis and Hepatocellular Carcinoma. Archives of Medical Research 2007;38:612-20. [DOI: 10.1016/j.arcmed.2006.09.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
184 Perini MV, Starkey G, Fink MA, Bhandari R, Muralidharan V, Jones R, Christophi C. From minimal to maximal surgery in the treatment of hepatocarcinoma: A review. World J Hepatol 2015; 7(1): 93-100 [PMID: 25625000 DOI: 10.4254/wjh.v7.i1.93] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
185 Juran BD, Lazaridis KN. Genetics of Hepatobiliary Diseases. Clinical Gastroenterology and Hepatology 2006;4:548-57. [DOI: 10.1016/j.cgh.2006.03.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
186 Volk ML, Marrero JA. Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep. 2008;10:60-66. [PMID: 18417044 DOI: 10.1007/s11894-008-0010-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
187 Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007;67:2497-2507. [PMID: 17363567 DOI: 10.1158/0008-5472.can-06-3075] [Cited by in Crossref: 324] [Cited by in F6Publishing: 174] [Article Influence: 23.1] [Reference Citation Analysis]
188 Shih YL, Shyu RY, Hsieh CB, Lai HC, Liu KY, Chu TY, Lin YW. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer. 2006;107:579-590. [PMID: 16795071 DOI: 10.1002/cncr.22023] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 5.1] [Reference Citation Analysis]
189 Jafri W, Kamran M. Hepatocellular Carcinoma in Asia: A Challenging Situation. Euroasian J Hepatogastroenterol 2019;9:27-33. [PMID: 31988864 DOI: 10.5005/jp-journals-10018-1292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
190 Ierardi E, Rosania R, Zotti M, Giorgio F, Prencipe S, Valle ND, Francesco VD, Panella C. From chronic liver disorders to hepatocellular carcinoma: Molecular and genetic pathways. World J Gastrointest Oncol 2010; 2(6): 259-264 [PMID: 21160638 DOI: 10.4251/wjgo.v2.i6.259] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
191 Feng M, Ben-Josef E. Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol. 2011;21:271-277. [PMID: 21939856 DOI: 10.1016/j.semradonc.2011.05.002] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 7.4] [Reference Citation Analysis]
192 Jung KH, Yoo W, Stevenson HL, Deshpande D, Shen H, Gagea M, Yoo SY, Wang J, Eckols TK, Bharadwaj U, Tweardy DJ, Beretta L. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice. Clin Cancer Res 2017;23:5537-46. [PMID: 28533225 DOI: 10.1158/1078-0432.CCR-16-2253] [Cited by in Crossref: 38] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
193 Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, Tsugane S; JPHC Study Group. Impact of viral load of hepatitis C on the incidence of hepatocellular carcinoma: A population-based cohort study (JPHC Study). Cancer Lett. 2011;300:173-179. [PMID: 21035947 DOI: 10.1016/j.canlet.2010.10.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
194 Raoof M, Curley SA. Non-invasive radiofrequency-induced targeted hyperthermia for the treatment of hepatocellular carcinoma. Int J Hepatol 2011;2011:676957. [PMID: 21994866 DOI: 10.4061/2011/676957] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
195 Zhang Z, Lei B, Chai W, Liu R, Li T. Increased expression of insulin-like growth factor-1 receptor predicts poor prognosis in patients with hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e17680. [PMID: 31689787 DOI: 10.1097/MD.0000000000017680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
196 Bedossa P, Paradis V. Hepatocellular Carcinoma. Practical Hepatic Pathology: A Diagnostic Approach. Elsevier; 2011. pp. 489-501. [DOI: 10.1016/b978-0-443-06803-4.00035-6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
197 Schoppmeyer K, Weis S, Mössner J, Fleig WE. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;3:CD006745. [PMID: 19588401 DOI: 10.1002/14651858.cd006745.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
198 Casadei Gardini A, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. Eur J Cancer. 2017;86:106-114. [PMID: 28985579 DOI: 10.1016/j.ejca.2017.09.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
199 Chavez PR, Lian F, Chung J, Liu C, Paiva SA, Seitz HK, Wang XD. Long-term ethanol consumption promotes hepatic tumorigenesis but impairs normal hepatocyte proliferation in rats. J Nutr 2011;141:1049-55. [PMID: 21490289 DOI: 10.3945/jn.110.136531] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
200 Oishi K, Itamoto T, Kobayashi T, Oshita A, Amano H, Ohdan H, Tashiro H, Asahara T. Hepatectomy for hepatocellular carcinoma in elderly patients aged 75 years or more. J Gastrointest Surg. 2009;13:695-701. [PMID: 19050982 DOI: 10.1007/s11605-008-0758-6] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis]
201 Díaz-Montaña JJ, Díaz-Díaz N, Gómez-Vela F. GFD-Net: A novel semantic similarity methodology for the analysis of gene networks. J Biomed Inform 2017;68:71-82. [PMID: 28274758 DOI: 10.1016/j.jbi.2017.02.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
202 Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 2009;49:1563-70. [PMID: 19399911 DOI: 10.1002/hep.22793] [Cited by in Crossref: 103] [Cited by in F6Publishing: 94] [Article Influence: 8.6] [Reference Citation Analysis]
203 Ronot M, Pommier R, Dioguardi Burgio M, Purcell Y, Nahon P, Vilgrain V. Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake. Br J Radiol 2018;91:20170436. [PMID: 29446324 DOI: 10.1259/bjr.20170436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
204 Rajas F, Labrune P, Mithieux G. Glycogen storage disease type 1 and diabetes: Learning by comparing and contrasting the two disorders. Diabetes & Metabolism 2013;39:377-87. [DOI: 10.1016/j.diabet.2013.03.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
205 Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;CD001199. [PMID: 19160192 DOI: 10.1002/14651858.cd001199.pub2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
206 Talamini R, Polesel J, Montella M, Dal Maso L, Crispo A, Tommasi LG, Izzo F, Crovatto M, La Vecchia C, Franceschi S. Food groups and risk of hepatocellular carcinoma: A multicenter case-control study in Italy. Int J Cancer. 2006;119:2916-2921. [PMID: 16998792 DOI: 10.1002/ijc.22267] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 4.7] [Reference Citation Analysis]
207 Liu C, Shen J, Pan C, Yang L, Mou S, Wang H, Liang Y. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma. Am J Clin Pathol 2010;134:235-41. [PMID: 20660326 DOI: 10.1309/AJCPA6C6NOGFLYIR] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
208 Ertel AE, Shah SA. Surgical Approaches to Hepatocellular Carcinoma. Semin Roentgenol 2016;51:88-94. [PMID: 27105963 DOI: 10.1053/j.ro.2016.02.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Moriwaki H, Shiraki M, Fukushima H, Shimizu M, Iwasa J, Naiki T, Nagaki M. Long-term outcome of branched-chain amino acid treatment in patients with liver cirrhosis. Hepatol Res. 2008;38:S102-S106. [PMID: 19125940 DOI: 10.1111/j.1872-034x.2008.00434.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
210 Marquardt JU, Quasdorff M, Varnholt H, Curth HM, Mesghenna S, Protzer U, Goeser T, Nierhoff D. Neighbor of Punc E11, a novel oncofetal marker for hepatocellular carcinoma. Int J Cancer. 2011;128:2353-2363. [PMID: 20658536 DOI: 10.1002/ijc.25567] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
211 Mathur AK, Schaubel DE, Gong Q, Guidinger MK, Merion RM. Racial and ethnic disparities in access to liver transplantation. Liver Transpl 2010;16:1033-40. [PMID: 20818740 DOI: 10.1002/lt.22108] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
212 Jepsen P, Vilstrup H, Tarone RE, Friis S, Sørensen HT. Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. Int J Cancer 2007;121:1624-6. [PMID: 17557292 DOI: 10.1002/ijc.22860] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
213 Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330. [PMID: 18430871 DOI: 10.1148/radiol.2472061331] [Cited by in Crossref: 274] [Cited by in F6Publishing: 231] [Article Influence: 21.1] [Reference Citation Analysis]
214 Qi Y, Chen X, Chan CY, Li D, Yuan C, Yu F, Lin MC, Yew DT, Kung HF, Lai L. Two-dimensional differential gel electrophoresis/analysis of diethylnitrosamine induced rat hepatocellular carcinoma. Int J Cancer. 2008;122:2682-2688. [PMID: 18351647 DOI: 10.1002/ijc.23464] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
215 Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, Wege H. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer. 2013;133:2165-2171. [PMID: 23616258 DOI: 10.1002/ijc.28230] [Cited by in Crossref: 142] [Cited by in F6Publishing: 135] [Article Influence: 17.8] [Reference Citation Analysis]
216 Monga SP. Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol. 2011;43:1021-1029. [PMID: 19747566 DOI: 10.1016/j.biocel.2009.09.001s1357-2725(09)00244-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
217 Zhao GS, Li C, Liu Y, Ren ZZ, Yuan XL, Zhou J, Zhang YW, Zhang M. 350-560 μm gelatin sponge particles combined with transcatheter arterial chemoembolization for the treatment of elderly hepatocellular carcinoma: The safety and efficacy. Medicine (Baltimore) 2017;96:e6629. [PMID: 28422858 DOI: 10.1097/MD.0000000000006629] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
218 Bolondi L. State of the art: hepatocellular carcinoma. Future Oncology 2014;10:1-6. [DOI: 10.2217/fon.14.215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
219 Giannelli G, Antonaci S. Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J Clin Gastroenterol 2006;40:842-6. [PMID: 17016142 DOI: 10.1097/01.mcg.0000225543.11503.17] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
220 Walter SR, Thein H, Amin J, Gidding HF, Ward K, Law MG, George J, Dore GJ. Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006. Journal of Hepatology 2011;54:879-86. [DOI: 10.1016/j.jhep.2010.08.035] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
221 Huang LL, Zhang Y, Zhang JX, He LJ, Lai YR, Liao YJ, Tian XP, Deng HX, Liang YJ, Kung HF, Xie D, Zhu SL. Overexpression of NKX6.1 is closely associated with progressive features and predicts unfavorable prognosis in human primary hepatocellular carcinoma. Tumour Biol 2015;36:4405-15. [PMID: 25596704 DOI: 10.1007/s13277-015-3080-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
222 Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res. 2009;39:177-186. [PMID: 19208038 DOI: 10.1111/j.1872-034x.2008.00449.x] [Cited by in Crossref: 222] [Cited by in F6Publishing: 117] [Article Influence: 22.2] [Reference Citation Analysis]
223 Frau M, Feo F, Pascale RM. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis. J Hepatol. 2013;59:830-841. [PMID: 23665184 DOI: 10.1016/j.jhep.2013.04.031] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 8.8] [Reference Citation Analysis]
224 Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One. 2011;6:e28486. [PMID: 22174818 DOI: 10.1371/journal.pone.0028486] [Cited by in Crossref: 199] [Cited by in F6Publishing: 200] [Article Influence: 19.9] [Reference Citation Analysis]
225 Wang H, Liu J, Hu X, Liu S, He B. Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in Hepatocellular Carcinoma. Med Sci Monit 2016;22:3694-704. [PMID: 27739418 DOI: 10.12659/msm.899773] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
226 Nathan H, Hyder O, Mayo SC, Hirose K, Wolfgang CL, Choti MA, Pawlik TM. Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg. 2013;258:1022-1027. [PMID: 23299519 DOI: 10.1097/sla.0b013e31827da749] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
227 Luther DJ, Ohanyan V, Shamhart PE, Hodnichak CM, Sisakian H, Booth TD, Meszaros JG, Bishayee A. Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma. Invest New Drugs 2011;29:380-91. [DOI: 10.1007/s10637-009-9332-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
228 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 308] [Article Influence: 31.0] [Reference Citation Analysis]
229 Lanford RE, Guerra B, Lee H. Hepatitis C virus genotype 1b chimeric replicon containing genotype 3 NS5A domain. Virology 2006;355:192-202. [DOI: 10.1016/j.virol.2006.07.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
230 Song IH, Kim KS. Current status of liver diseases in Korea: hepatocellular carcinoma. Korean J Hepatol. 2009;15 Suppl 6:S50-S59. [PMID: 20037280 DOI: 10.3350/kjhep.2009.15.s6.s50] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
231 Ouedraogo W, Tran-Van Nhieu J, Baranes L, Lin SJ, Decaens T, Laurent A, Djabbari M, Pigneur F, Duvoux C, Kobeiter H. [Evaluation of noninvasive diagnostic criteria for hepatocellular carcinoma on pretransplant MRI (2010): correlation between MR imaging features and histological features on liver specimen]. J Radiol. 2011;92:688-700. [PMID: 21819911 DOI: 10.1016/j.jradio.2011.03.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
232 Welsch C, Albrecht M, Maydt J, Herrmann E, Welker MW, Sarrazin C, Scheidig A, Lengauer T, Zeuzem S. Structural and functional comparison of the non-structural protein 4B in flaviviridae. J Mol Graph Model. 2007;26:546-557. [PMID: 17507273 DOI: 10.1016/j.jmgm.2007.03.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
233 Jin YJ, Chung YH, Kim JA, Park WH, Lee D, Seo DD, Ryu SH, Jang MK, Yu E, Lee YJ. Factors predisposing metastatic tumor antigen 1 overexpression in hepatitis B virus associated hepatocellular carcinoma. Dig Dis Sci. 2012;57:2917-2923. [PMID: 22777614 DOI: 10.1007/s10620-012-2296-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
234 Yin YH, Li YY, Qiao H, Wang HC, Yang XA, Zhang HG, Pang XW, Zhang Y, Chen WF. TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma. Br J Cancer. 2005;93:458-463. [PMID: 16106251 DOI: 10.1038/sj.bjc.6602716] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
235 Witjes CD, Karim-Kos HE, Visser O, van den Akker SA, de Vries E, Ijzermans JN, de Man RA, Coebergh JW, Verhoef C. Hepatocellular carcinoma in a low-endemic area: rising incidence and improved survival. Eur J Gastroenterol Hepatol. 2012;24:450-457. [PMID: 22273986 DOI: 10.1097/MEG.0b013e32835030ce] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
236 Kim TM, Yim SH, Shin SH, Xu HD, Jung YC, Park CK, Choi JY, Park WS, Kwon MS, Fiegler H, Carter NP, Rhyu MG, Chung YJ. Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer. 2008;123:2808-2815. [PMID: 18803288 DOI: 10.1002/ijc.23901] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
237 Yang JQ, Pan GD, Chu GP, Liu Z, Liu Q, Xiao Y, Yuan L. Interferon-alpha restrains growth and invasive potential of hepatocellular carcinoma induced by hepatitis B virus X protein. World J Gastroenterol 2008; 14(36): 5564-5569 [PMID: 18810776 DOI: 10.3748/wjg.14.5564] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
238 Hamed O, Kimchi ET, Sehmbey M, Gusani NJ, Kaifi JT, Staveley-O’Carroll K. Impact of genetic targets on cancer therapy: hepatocellular cancer. Adv Exp Med Biol. 2013;779:67-90. [PMID: 23288636 DOI: 10.1007/978-1-4614-6176-0_4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
239 Badar S, Badar S, Khubaib B, Khubaib B, Idrees M, Idrees M, Hussain A, Hussain A, Awan Z, Awan Z, Butt S, Butt S, Afzal S, Afzal S, Akram M, Akram M, Fatima Z, Fatima Z, Aftab M, Aftab M, Saleem S, Saleem S, Munir S, Munir S, Rauff B, Rauff B, Naudhani M, Naudhani M, Liaquat A, Ali L, Ali M, Ali M, Rehman I, Rehman I. Association of Hepatitis C Virus With Insulin Resistance: Evidences From Animal Studies and Clinical Studie. Hepat Mon 2012;12:11-5. [DOI: 10.5812/hepatmon.4295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
240 Wang X, Chen Y, Han QB, Chan CY, Wang H, Liu Z, Cheng CH, Yew DT, Lin MC, He ML. Proteomic identification of molecular targets of gambogic acid: role of stathmin in hepatocellular carcinoma. Proteomics. 2009;9:242-253. [PMID: 19086098 DOI: 10.1002/pmic.200800155] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 4.9] [Reference Citation Analysis]
241 Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010;16:4688-94. [PMID: 20713493 DOI: 10.1158/1078-0432.CCR-09-1811] [Cited by in Crossref: 92] [Cited by in F6Publishing: 59] [Article Influence: 8.4] [Reference Citation Analysis]
242 Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T, Oka M. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer 2007;97:1399-403. [PMID: 17940509 DOI: 10.1038/sj.bjc.6604034] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
243 Morgenlander JC, Goldstein LB. Recurrent transient ischemic attacks and stroke in association with an internal carotid artery web. Stroke. 1991;22:94-98. [PMID: 1987677 DOI: 10.1007/s12032-009-9343-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.4] [Reference Citation Analysis]
244 Guerrero-Misas M, Rodríguez-Perálvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol 2015; 7(4): 649-661 [PMID: 25866602 DOI: 10.4254/wjh.v7.i4.649] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
245 Wang B, Huang G, Wang D, Li A, Xu Z, Dong R, Zhang D, Zhou W. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 2010;53:508-518. [PMID: 20561699 DOI: 10.1016/j.jhep.2010.03.026] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 7.4] [Reference Citation Analysis]
246 Davila JA, Kramer JR, Duan Z, Richardson PA, Tyson GL, Sada YH, Kanwal F, El-Serag HB. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57:1858-1868. [PMID: 23359313 DOI: 10.1002/hep.26287] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
247 Tan H, Martin P. Care of the Liver Transplant Candidate. Clinics in Liver Disease 2011;15:779-806. [DOI: 10.1016/j.cld.2011.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
248 Seren S, Lieberman R, Bayraktar UD, Heath E, Sahin K, Andic F, Kucuk O. Lycopene in cancer prevention and treatment. Am J Ther. 2008;15:66-81. [PMID: 18223356 DOI: 10.1097/mjt.0b013e31804c7120] [Cited by in Crossref: 53] [Cited by in F6Publishing: 12] [Article Influence: 4.1] [Reference Citation Analysis]
249 El-serag HB, Lechel A, Rudolph KL. Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 142-56. [DOI: 10.1016/b978-1-4377-0881-3.00010-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
250 Fu Q, Yu Z. Phosphoglycerate kinase 1 (PGK1) in cancer: A promising target for diagnosis and therapy. Life Sci 2020;256:117863. [PMID: 32479953 DOI: 10.1016/j.lfs.2020.117863] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
251 Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28:3526-3536. [PMID: 19617899 DOI: 10.1038/onc.2009.211] [Cited by in Crossref: 484] [Cited by in F6Publishing: 468] [Article Influence: 40.3] [Reference Citation Analysis]
252 Cui Z, Yu X, Guo L, Wei Y, Zheng S, Li W, Chen P, Zhu J, Peng J. Combined analysis of serum alpha-fetoprotein and MAGE-A3-specific cytotoxic T lymphocytes in peripheral blood for diagnosis of hepatocellular carcinoma. Dis Markers. 2013;35:915-923. [PMID: 24427779 DOI: 10.1155/2013/907394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
253 Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, Ikeda H, Shiina S, Kawabe T, Omata M. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954-1961. [PMID: 19434742 DOI: 10.1002/hep.22870] [Cited by in Crossref: 262] [Cited by in F6Publishing: 245] [Article Influence: 21.8] [Reference Citation Analysis]
254 Mumtaz K, Patel N, Modi RM, Patel V, Hinton A, Hanje J, Black SM, Krishna S. Trends and outcomes of transarterial chemoembolization in hepatocellular carcinoma: a national survey. Hepatobiliary Pancreat Dis Int 2017;16:624-30. [PMID: 29291782 DOI: 10.1016/S1499-3872(17)60077-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
255 Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, Hosaka T, Akuta N, Suzuki Y, Suzuki F, Sezaki H. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. J Hepatol. 2006;44:1089-1097. [PMID: 16618514 DOI: 10.1016/j.jhep.2006.02.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
256 Cho Y, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY, Yoon JH. Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma. Dig Dis Sci 2016;61:2568-77. [PMID: 27074919 DOI: 10.1007/s10620-016-4158-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
257 Yang CH, Chiu YC, Chen CH, Chen CH, Tsai MC, Chuah SK, Lee CH, Hu TH, Hung CH. Diabetes mellitus is associated with gastroesophageal variceal bleeding in cirrhotic patients. Kaohsiung J Med Sci 2014;30:515-20. [PMID: 25438683 DOI: 10.1016/j.kjms.2014.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
258 Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, Kim JH, Hwang JE, Jang HJ, Lee HS, Kim SC, Jeong W, Kim SS, Park ES, Heo J, Kim YJ, Kim DG, Leem SH, Kaseb A, Hassan MM, Cha M, Chu IS, Johnson RL, Park YY, Lee JS. Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma. Clin Cancer Res 2016;22:1256-64. [PMID: 26459179 DOI: 10.1158/1078-0432.CCR-15-1447] [Cited by in Crossref: 60] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
259 Hashimoto R, Kanda M, Takami H, Shimizu D, Oya H, Hibino S, Okamura Y, Yamada S, Fujii T, Nakayama G. Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. Oncol Lett. 2015;9:1201-1206. [PMID: 25663882 DOI: 10.3892/ol.2014.2823] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
260 Hayashi K, Ina H, Tezuka M, Okada Y, Irie T. Local therapeutic results of computed tomography-guided transcatheter arterial chemoembolization for hepatocellular carcinoma: results of 265 tumors in 79 patients. Cardiovasc Intervent Radiol. 2007;30:1144-1155. [PMID: 17909884 DOI: 10.1007/s00270-007-9169-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
261 Waghray A, Balci B, El-Gazzaz G, Kim R, Pelley R, Narayanan Menon KV, Estfan B, Romero-Marrero C, Aucejo F. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant. 2013;27:555-561. [PMID: 23758296 DOI: 10.1111/ctr.12150] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
262 Mason MC, Massarweh NN, Salami A, Sultenfuss MA, Anaya DA. Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma. HPB (Oxford) 2015;17:1137-44. [PMID: 26374137 DOI: 10.1111/hpb.12487] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
263 Choi JG, Chung YH, Kim JA, Jin YJ, Park WH, Lee D, Shim JH, Lee YS, Seo DD, Jang MK, Kim KM, Lim YS, Lee HC, Lee YS, Yu E, Lee YJ. High HBV-DNA titer in surrounding liver rather than in hepatocellular carcinoma tissue predisposes to recurrence after curative surgical resection. J Clin Gastroenterol 2012;46:413-9. [PMID: 22105184 DOI: 10.1097/MCG.0b013e3182371285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
264 Blechacz B, Splinter PL, Greiner S, Myers R, Peng KW, Federspiel MJ, Russell SJ, LaRusso NF. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 2006;44:1465-77. [PMID: 17133484 DOI: 10.1002/hep.21437] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 5.9] [Reference Citation Analysis]
265 Jin YJ, Lee JW, Park SW, Lee JI, Lee DH, Kim YS, Cho SG, Jeon YS, Lee KY, Ahn SI. Survival outcome of patients with spontaneously ruptured hepatocellular carcinoma treated surgically or by transarterial embolization. World J Gastroenterol 2013; 19(28): 4537-4544 [PMID: 23901230 DOI: 10.3748/wjg.v19.i28.4537] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
266 Schiano TD, Martin P. Management of HCV infection and liver transplantation. Int J Med Sci 2006;3:79-83. [PMID: 16614748 DOI: 10.7150/ijms.3.79] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
267 Eswaran SL, Pierce K, Weaver F, Rogers T, Brems JJ, Sontag SJ, Borge M. Transarterial chemoembolization for HCC in patients with extensive liver transplantation waiting times. Angiology 2012;63:206-12. [PMID: 21733955 DOI: 10.1177/0003319711411705] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
268 De Minicis S, Brenner DA. Oxidative stress in alcoholic liver disease: role of NADPH oxidase complex. J Gastroenterol Hepatol. 2008;23 Suppl 1:S98-S103. [PMID: 18336675 DOI: 10.1111/j.1440-1746.2007.05277.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 6.5] [Reference Citation Analysis]
269 Yu MA, Liang P, Yu XL, Han ZY, Dong XJ, Wang YU, Cheng C, Li X. Multiple courses of immunotherapy with different immune cell types for patients with hepatocellular carcinoma after microwave ablation. Exp Ther Med. 2015;10:1460-1466. [PMID: 26622507 DOI: 10.3892/etm.2015.2681] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
270 Biasiolo A, Martini A, Pontisso P. New biomarkers for clinical management of hepatitis C virus infected patients. World J Clin Infect Dis 2015; 5(4): 59-66 [DOI: 10.5495/wjcid.v5.i4.59] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
271 Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, Rosmorduc O, Ratziu V. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther 2017;46:856-63. [PMID: 28857208 DOI: 10.1111/apt.14261] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 10.8] [Reference Citation Analysis]
272 Kawaguchi T, Sata M. Importance of hepatitis C virus-associated insulin resistance: Therapeutic strategies for insulin sensitization. World J Gastroenterol 2010; 16(16): 1943-1952 [PMID: 20419831 DOI: 10.3748/wjg.v16.i16.1943] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
273 Ding Y, Chen B, Wang S, Zhao L, Chen J, Ding Y, Chen L, Luo R. Overexpression of Tiam1 in hepatocellular carcinomas predicts poor prognosis of HCC patients. Int J Cancer. 2009;124:653-658. [PMID: 18972435 DOI: 10.1002/ijc.23954] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
274 Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol 2015;141:861-76. [DOI: 10.1007/s00432-014-1806-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 67] [Article Influence: 8.4] [Reference Citation Analysis]
275 Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010;61:317-28. [PMID: 20059340 DOI: 10.1146/annurev.med.080608.100623] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 14.5] [Reference Citation Analysis]
276 Cui JF, Liu YK, Zhou HJ, Kang XN, Huang C, He YF, Tang ZY, Uemura T. Screening serum hepatocellular carcinoma-associated proteins by SELDI-based protein spectrum analysis. World J Gastroenterol 2008; 14(8): 1257-1262 [PMID: 18300354 DOI: 10.3748/wjg.14.1257] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
277 Aparo S, Goel S, Lin D, Ohri N, Schwartz JM, Lo Y, Kaubisch A. Survival analysis of Hispanics in a cohort of patients with hepatocellular carcinoma. Cancer 2014;120:3683-90. [PMID: 25081065 DOI: 10.1002/cncr.28867] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
278 Xiao J, Ding Y, Huang J, Li Q, Liu Y, Ni W, Zhang Y, Zhu Y, Chen L, Chen B. The association of HMGB1 gene with the prognosis of HCC. PLoS One. 2014;9:e89097. [PMID: 24586525 DOI: 10.1371/journal.pone.0089097] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
279 Omino R, Mittal S, Kramer JR, Chayanupatkul M, Richardson P, Kanwal F. The Validity of HCC Diagnosis Codes in Chronic Hepatitis B Patients in the Veterans Health Administration. Dig Dis Sci 2017;62:1180-5. [DOI: 10.1007/s10620-017-4503-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
280 Yang H, Liu H, Tian L, Song R, Song X, Yin D, Liang Y, Qu L, Jiang H, Liu J, Liu L. Expression and prognostic value of ING3 in human primary hepatocellular carcinoma. Exp Biol Med (Maywood) 2012;237:352-61. [DOI: 10.1258/ebm.2011.011346] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
281 Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology. 2013;58:150-157. [PMID: 23389758 DOI: 10.1002/hep.26300] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 7.9] [Reference Citation Analysis]
282 Jin Y, Lee J, Lee OH, Chung HJ, Kim YS, Lee JI, Cho SG, Jeon YS, Lee KY, Ahn S, Shin WY. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion: Recurrent hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:1056-64. [DOI: 10.1111/jgh.12507] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
283 Chhatwal J, Chen Q, Bethea ED, Hur C, Spaulding AC, Kanwal F. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Aliment Pharmacol Ther 2019;50:66-74. [PMID: 31115920 DOI: 10.1111/apt.15291] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
284 Idrees M, Rafique S, Rehman IU, Akbar H, Yousaf MZ, Butt S, Awan Z, Manzoor S, Akram M, Aftab M, Khubaib B, Riazuddin S. Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol 2009; 15(40): 5080-5085 [PMID: 19860002 DOI: 10.3748/wjg.15.5080] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
285 Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 2010;45:1272-1282. [PMID: 20625772 DOI: 10.1007/s00535-010-0278-5] [Cited by in Crossref: 106] [Cited by in F6Publishing: 97] [Article Influence: 9.6] [Reference Citation Analysis]
286 李颖, 丁洋, 王雪莲, 刘沛. 慢性丙型肝炎患者血清HCV RNA, ALT与肝脏病理间的关系. 世界华人消化杂志 2006; 14(9): 916-919 [DOI: 10.11569/wcjd.v14.i9.916] [Reference Citation Analysis]
287 Jaka H, Mshana SE, Rambau PF, Masalu N, Chalya PL, Kalluvya SE. Hepatocellular carcinoma: clinicopathological profile and challenges of management in a resource-limited setting. World J Surg Oncol 2014;12:246. [PMID: 25085449 DOI: 10.1186/1477-7819-12-246] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
288 Sellers MT, Huggins S, Kegley K, Pollinger HS, Shrestha R, Johnson MW, Stein LL, Panjala C, Tan M, Arepally A. Multivariate analysis of prognostic factors for survival following doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2013;24:647-654. [PMID: 23384831 DOI: 10.1016/j.jvir.2012.12.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
289 Bhalla K, Hwang BJ, Dewi RE, Twaddel W, Goloubeva OG, Wong KK, Saxena NK, Biswal S, Girnun GD. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila). 2012;5:544-552. [PMID: 22467080 DOI: 10.1158/1940-6207.CAPR-11-0228.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
290 Ling G, Sugathan A, Mazor T, Fraenkel E, Waxman DJ. Unbiased, genome-wide in vivo mapping of transcriptional regulatory elements reveals sex differences in chromatin structure associated with sex-specific liver gene expression. Mol Cell Biol 2010;30:5531-44. [PMID: 20876297 DOI: 10.1128/MCB.00601-10] [Cited by in Crossref: 77] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
291 Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2015;1:CD006745. [PMID: 25620061 DOI: 10.1002/14651858.CD006745.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
292 Asmis T, Balaa F, Scully L, Papadatos D, Marginean C, Fasih N, Shaw-Stiffel T, Goel R. Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol 2010;17:6-12. [PMID: 20404972 DOI: 10.3747/co.v17i2.555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
293 Sullivan KM, Groeschl RT, Turaga KK, Tsai S, Christians KK, White SB, Rilling WS, Pilgrim CH, Gamblin TC. Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: a Western perspective. J Surg Oncol. 2014;109:95-97. [PMID: 24122764 DOI: 10.1002/jso.23448] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
294 Ande A, Chaar M, Ait-Oudhia S. Multiscale systems pharmacological analysis of everolimus action in hepatocellular carcinoma. J Pharmacokinet Pharmacodyn 2018;45:607-20. [PMID: 29725796 DOI: 10.1007/s10928-018-9590-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
295 Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009;49:821-31. [PMID: 19101982 DOI: 10.1002/hep.22695] [Cited by in Crossref: 109] [Cited by in F6Publishing: 98] [Article Influence: 9.1] [Reference Citation Analysis]
296 Wong CR, Garcia RT, Trinh HN, Lam KD, Ha NB, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting. Dig Dis Sci. 2009;54:2712-2721. [PMID: 19876735 DOI: 10.1007/s10620-009-1015-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
297 Latasa MU, Salis F, Urtasun R, Garcia-Irigoyen O, Elizalde M, Uriarte I, Santamaria M, Feo F, Pascale RM, Prieto J, Berasain C, Avila MA. Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system. PLoS One 2012;7:e52711. [PMID: 23285165 DOI: 10.1371/journal.pone.0052711] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
298 Murata M, Matsuzaki K, Yoshida K, Sekimoto G, Tahashi Y, Mori S, Uemura Y, Sakaida N, Fujisawa J, Seki T, Kobayashi K, Yokote K, Koike K, Okazaki K. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-β signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology 2009;49:1203-17. [DOI: 10.1002/hep.22765] [Cited by in Crossref: 108] [Cited by in F6Publishing: 112] [Article Influence: 8.3] [Reference Citation Analysis]
299 Okuma HS, Kondo S. Trends in the development of MET inhibitors for hepatocellular carcinoma. Future Oncol 2016;12:1275-86. [PMID: 26984595 DOI: 10.2217/fon.16.3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
300 Xiao W, Zhao S, Shen F, Liang J, Chen J. Overexpression of CD147 is associated with poor prognosis, tumor cell migration and ERK signaling pathway activation in hepatocellular carcinoma. Exp Ther Med 2017;14:2637-42. [PMID: 28962206 DOI: 10.3892/etm.2017.4818] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
301 Hsu PC, Buxton JA, Tu AW, Hill WD, Yu A, Krajden M. Publicly funded pegylated interferon-alpha treatment in British Columbia: disparities in treatment patterns for people with hepatitis C. Can J Gastroenterol 2008;22:359-64. [PMID: 18414709 DOI: 10.1155/2008/243607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
302 Grosfeld JL, Otte J. Liver Tumors in Children. In: Carachi R, Grosfeld JL, Azmy AF, editors. The Surgery of Childhood Tumors. Berlin: Springer Berlin Heidelberg; 2008. pp. 227-60. [DOI: 10.1007/978-3-540-29734-5_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
303 Balci D, Dayangac M, Yaprak O, Akin B, Duran C, Killi R, Yuzer Y, Tokat Y. Living donor liver transplantation for hepatocellular carcinoma: a single center analysis of outcomes and impact of different selection criteria: Living donor liver transplantation for hepatocellular carcinoma. Transplant International 2011;24:1075-83. [DOI: 10.1111/j.1432-2277.2011.01311.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
304 Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon 2012;12:e7635. [PMID: 23233865 DOI: 10.5812/hepatmon.7635] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
305 Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology. 2008;15:91-101. [PMID: 18602801 DOI: 10.1016/j.pathophys.2008.05.001] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 5.6] [Reference Citation Analysis]
306 Niwa Y, Ishikawa K, Ishigami M, Honda T, Achiwa K, Izumoto T, Maekawa R, Hosokawa K, Iida A, Seino Y, Hamada Y, Goto H, Oiso Y, Arima H, Tsunekawa S. Effect of hyperglycemia on hepatocellular carcinoma development in diabetes. Biochem Biophys Res Commun 2015;463:344-50. [PMID: 26022129 DOI: 10.1016/j.bbrc.2015.05.066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
307 Murugavel KG, Naranatt PP, Shankar EM, Mathews S, Raghuram K, Rajasambandam P, Jayanthi V, Surendran R, Murali A, Srinivas U, Palaniswamy KR, Srikumari D, Thyagarajan SP. Prevalence of aflatoxin B1 in liver biopsies of proven hepatocellular carcinoma in India determined by an in-house immunoperoxidase test. J Med Microbiol 2007;56:1455-9. [PMID: 17965344 DOI: 10.1099/jmm.0.47151-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
308 Matsubara T, Kanto T, Kuroda S, Yoshio S, Higashitani K, Kakita N, Miyazaki M, Sakakibara M, Hiramatsu N, Kasahara A, Tomimaru Y, Tomokuni A, Nagano H, Hayashi N, Takehara T. TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology. 2013;57:1416-1425. [PMID: 22815256 DOI: 10.1002/hep.25965] [Cited by in Crossref: 81] [Cited by in F6Publishing: 88] [Article Influence: 10.1] [Reference Citation Analysis]
309 Lai MW, Huang SF, Lin SM, Chen TC, Lin CY, Yeh CN, Yeh TS, Chen MF, Yeh CT. Expression of the HCRP1 mRNA in HCC as an independent predictor of disease-free survival after surgical resection. Hepatol Res 2009;39:164-76. [PMID: 19208037 DOI: 10.1111/j.1872-034X.2008.00413.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
310 Ying X, Han SX, Wang JL, Zhou X, Jin GH, Jin L, Wang H, Wu L, Zhang J, Zhu Q. Serum peptidome patterns of hepatocellular carcinoma based on magnetic bead separation and mass spectrometry analysis. Diagn Pathol 2013;8:130. [PMID: 23915185 DOI: 10.1186/1746-1596-8-130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
311 McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A. Emerging MEK inhibitors. Expert Opin Emerg Drugs. 2010;15:203-223. [PMID: 20151845 DOI: 10.1517/14728210903282760] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
312 Rossi M, Lipworth L, Maso LD, Talamini R, Montella M, Polesel J, McLaughlin JK, Parpinel M, Franceschi S, Lagiou P. Dietary glycemic load and hepatocellular carcinoma with or without chronic hepatitis infection. Ann Oncol. 2009;20:1736-1740. [PMID: 19549710 DOI: 10.1093/annonc/mdp058] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
313 Bhalla K, Hwang BJ, Dewi RE, Twaddel W, Goloubeva OG, Wong KK, Saxena NK, Biswal S, Girnun GD. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) 2012;5:544-52. [PMID: 22467080 DOI: 10.1158/1940-6207.CAPR-11-0228] [Cited by in Crossref: 97] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
314 Paprottka KJ, Todica A, Ilhan H, Rübenthaler J, Schoeppe F, Michl M, Heinemann V, Bartenstein P, Reiser MF, Paprottka PM. Evaluation of Visualization Using a 50/50 (Contrast Media/Glucose 5% Solution) Technique for Radioembolization as an Alternative to a Standard Sandwich Technique. Cardiovasc Intervent Radiol 2017;40:1740-7. [PMID: 28584948 DOI: 10.1007/s00270-017-1712-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
315 Evdokimova VN, Butterfield LH. Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer. Expert Opin Biol Ther 2008;8:325-36. [PMID: 18294103 DOI: 10.1517/14712598.8.3.325] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
316 Xie C, Song LB, Wu JH, Li J, Yun JP, Lai JM, Xie DY, Lin BL, Yuan YF, Li M. Upregulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma and contributes to hepatocarcinogenesis by downregulating FOXO3a. PLoS One. 2012;7:e40607. [PMID: 22815774 DOI: 10.1371/journal.pone.0040607] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
317 Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME, Sherman M. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2009;7:104-113. [PMID: 18849011 DOI: 10.1016/j.cgh.2008.08.041] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 6.7] [Reference Citation Analysis]
318 Zhuo H, Tang J, Lin Z, Jiang R, Zhang X, Ji J, Wang P, Sun B. The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma. Mol Carcinog. 2016;55:209-219. [PMID: 25641194 DOI: 10.1002/mc.22270] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 14.3] [Reference Citation Analysis]
319 Guerriero E, Capone F, Accardo M, Sorice A, Costantini M, Colonna G, Castello G, Costantini S. GPX4 and GPX7 over-expression in human hepatocellular carcinoma tissues. Eur J Histochem 2015;59:2540. [PMID: 26708178 DOI: 10.4081/ejh.2015.2540] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
320 Yang X, Wang D, Dong W, Song Z, Dou K. Suppression of Na+/H + exchanger 1 by RNA interference or amiloride inhibits human hepatoma cell line SMMC-7721 cell invasion. Med Oncol. 2011;28:385-390. [PMID: 20151228 DOI: 10.1007/s12032-010-9447-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
321 Paprottka PM, Paprottka KJ, Walter A, Haug AR, Trumm CG, Lehner S, Fendler WP, Jakobs TF, Reiser MF, Zech CJ. Safety of Radioembolization with (90)Yttrium Resin Microspheres Depending on Coiling or No-Coiling of Aberrant/High-Risk Vessels. Cardiovasc Intervent Radiol 2015;38:946-56. [PMID: 25986465 DOI: 10.1007/s00270-015-1128-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
322 Magistri P, Leonard SY, Tang CM, Chan JC, Lee TE, Sicklick JK. The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. J Surg Res 2014;187:377-85. [PMID: 24439425 DOI: 10.1016/j.jss.2013.12.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
323 Lin Y, Yan M, Shih Y, Hsieh C. The basal body gene, RPGRIP1L, is a candidate tumour suppressor gene in human hepatocellular carcinoma. European Journal of Cancer 2009;45:2041-9. [DOI: 10.1016/j.ejca.2009.04.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
324 Chhatwal J, Chen Q, Aggarwal R. Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling. Infect Dis Clin North Am 2018;32:461-80. [PMID: 29778266 DOI: 10.1016/j.idc.2018.02.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
325 Ha NB, Ha NB, Ahmed A, Ayoub W, Daugherty TJ, Chang ET, Lutchman GA, Garcia G, Cooper AD, Keeffe EB, Nguyen MH. Risk factors for hepatocellular carcinoma in patients with chronic liver disease: a case–control study. Cancer Causes Control 2012;23:455-62. [DOI: 10.1007/s10552-012-9895-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
326 Thomas MB. Systemic therapy for hepatocellular carcinoma. Cancer J. 2008;14:123-127. [PMID: 18391618 DOI: 10.1097/ppo.0b013e31816a6058] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
327 Chang P, Chi C, Chau G, Li F, Tsai Y, Wu J, Wu Lee Y. DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control. Oncogene 2006;25:1991-2003. [DOI: 10.1038/sj.onc.1209239] [Cited by in Crossref: 96] [Cited by in F6Publishing: 93] [Article Influence: 6.0] [Reference Citation Analysis]
328 Breinig M, Rieker R, Eiteneuer E, Wertenbruch T, Haugg AM, Helmke BM, Schirmacher P, Kern MA. Differential expression of E-prostanoid receptors in human hepatocellular carcinoma. Int J Cancer. 2008;122:547-557. [PMID: 17918156 DOI: 10.1002/ijc.23098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
329 Yip-schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM. Resistance to Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors Correlates with Up-Regulation of the MEK/Extracellular Signal-Regulated Kinase Pathway in Hepatocellular Carcinoma Cells. J Pharmacol Exp Ther 2009;329:1063-70. [DOI: 10.1124/jpet.108.147306] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
330 Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, Lin HH, Wu SS, Lee CM, Changchien CS. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer. 2006;119:1946-1952. [PMID: 16708389 DOI: 10.1002/ijc.22045] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 5.7] [Reference Citation Analysis]
331 Kuppusamy P, Nagalingam A, Muniraj N, Saxena NK, Sharma D. Concomitant activation of ETS-like transcription factor-1 and Death Receptor-5 via extracellular signal-regulated kinase in withaferin A-mediated inhibition of hepatocarcinogenesis in mice. Sci Rep 2017;7:17943. [PMID: 29263422 DOI: 10.1038/s41598-017-18190-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
332 Bhat M, Yanagiya A, Graber T, Razumilava N, Bronk S, Zammit D, Zhao Y, Zakaria C, Metrakos P, Pollak M, Sonenberg N, Gores G, Jaramillo M, Morita M, Alain T. Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. Oncotarget 2017;8:50542-56. [PMID: 28881582 DOI: 10.18632/oncotarget.10671] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
333 Demir M, Nigemeier J, Kütting F, Bowe A, Schramm C, Hoffmann V, Waldschmidt D, Goeser T, Steffen HM. Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center. Infection 2015;43:153-62. [PMID: 25701223 DOI: 10.1007/s15010-015-0751-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
334 Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010;8:924-33; quiz e117. [PMID: 20713178 DOI: 10.1016/j.cgh.2010.06.032] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 7.5] [Reference Citation Analysis]
335 O’Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology. 2008;134:1764-1776. [PMID: 18471553 DOI: 10.1053/j.gastro.2008.02.028] [Cited by in Crossref: 120] [Cited by in F6Publishing: 87] [Article Influence: 9.2] [Reference Citation Analysis]
336 Fuke H, Sugimoto K, Shiraki K, Tanaka J, Beppu T, Yoneda K, Yamamoto N, Ito K, Takaki H, Nakatsuka A. Predictive factors for distant recurrence of HCV-related hepatocellular carcinoma after radiofrequency ablation combined with chemoembolization. Aliment Pharmacol Ther. 2008;27:1253-1260. [PMID: 18221404 DOI: 10.1111/j.1365-2036.2008.03627.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
337 Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev. 2010;36:43-53. [PMID: 19910122 DOI: 10.1016/j.ctrv.2009.10.002] [Cited by in Crossref: 120] [Cited by in F6Publishing: 103] [Article Influence: 10.0] [Reference Citation Analysis]
338 Goh WW, Lee YH, Ramdzan ZM, Chung MC, Wong L, Sergot MJ. A network-based maximum link approach towards MS identifies potentially important roles for undetected ARRB1/2 and ACTB in liver cancer progression. Int J Bioinform Res Appl 2012;8:155-70. [PMID: 22961449 DOI: 10.1504/IJBRA.2012.048967] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
339 Kaewnoonual N, Itharat A, Pongsawat S, Nilbu-Nga C, Kerdput V, Pradidarcheep W. Anti-angiogenic and anti-proliferative effects of Benja-ummarit extract in rats with hepatocellular carcinoma. Biomed Rep 2020;12:109-20. [PMID: 32042419 DOI: 10.3892/br.2020.1272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
340 Duan Y, Xu H, Luo X, Zhang H, He Y, Sun G, Sun X. Procyanidins from Nelumbo nucifera Gaertn. Seedpod induce autophagy mediated by reactive oxygen species generation in human hepatoma G2 cells. Biomedicine & Pharmacotherapy 2016;79:135-52. [DOI: 10.1016/j.biopha.2016.01.039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
341 Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. Biochim Biophys Acta 2012;1826:215-37. [PMID: 23393659 DOI: 10.1016/j.bbcan.2012.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 19] [Article Influence: 0.6] [Reference Citation Analysis]
342 Fang Y, Fu D, Tang W, Cai Y, Ma D, Wang H, Xue R, Liu T, Huang X, Dong L, Wu H, Shen X. Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2013;1833:559-72. [DOI: 10.1016/j.bbamcr.2012.11.020] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
343 Wang F, Zhou H, Yang Y, Xia X, Sun Q, Luo J, Cheng B. Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncol Rep. 2012;27:1170-1176. [PMID: 22218807 DOI: 10.3892/or.2012.1620] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
344 Xiangbing H, Yankai Z, Ming L, Yong L, Yu Z, Huiyong Z, Yingying C, Jing H, Yun X, Liang J, Rongyue C, Jingjing L. The fusion protein of HSP65 with tandem repeats of β-hCG acting as a potent tumor vaccine in suppressing hepatocarcinoma. International Immunopharmacology 2010;10:230-8. [DOI: 10.1016/j.intimp.2009.11.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
345 Moreno-Sánchez D. [Epidemiology and natural history of primary nonalcoholic fatty liver disease]. Gastroenterol Hepatol 2006;29:244-54. [PMID: 16584696 DOI: 10.1157/13085972] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
346 Murugavel KG, Mathews S, Jayanthi V, Shankar EM, Hari R, Surendran R, Vengatesan A, Raghuram K, Rajasambandam P, Murali A, Srinivas U, Palaniswamy KR, Pugazhendhi T, Thyagarajan SP. Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies. Int J Infect Dis 2008;12:e71-6. [PMID: 18658001 DOI: 10.1016/j.ijid.2008.04.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
347 Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem. 2006;387:349-360. [PMID: 16606331 DOI: 10.1515/bc.2006.047] [Cited by in Crossref: 183] [Cited by in F6Publishing: 84] [Article Influence: 12.2] [Reference Citation Analysis]
348 Lim Y, Kim WR. The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease. Clinics in Liver Disease 2008;12:733-46. [DOI: 10.1016/j.cld.2008.07.007] [Cited by in Crossref: 187] [Cited by in F6Publishing: 174] [Article Influence: 14.4] [Reference Citation Analysis]
349 Gervais DA, Goldberg SN, Brown DB, Soulen MC, Millward SF, Rajan DK. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol. 2009;20:S342-S347. [PMID: 19560023 DOI: 10.1016/j.jvir.2009.04.029] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
350 Takii Y, Abiru S, Fujioka H, Nakamura M, Komori A, Ito M, Taniguchi K, Daikoku M, Meda Y, Ohata K, Yano K, Shimoda S, Yatsuhashi H, Ishibashi H, Migita K. Expression of microsomal prostaglandin E synthase-1 in human hepatocelluar carcinoma. Liver Int 2007;27:989-96. [PMID: 17696939 DOI: 10.1111/j.1478-3231.2007.01530.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
351 Talal AH, Ding Y, Venuto CS, Chakan LM, McLeod A, Dharia A, Morse GD, Brown LS, Markatou M, Kharasch ED. Toward precision prescribing for methadone: Determinants of methadone deposition. PLoS One 2020;15:e0231467. [PMID: 32302325 DOI: 10.1371/journal.pone.0231467] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
352 Berenguer M. Hepatitis C virus in liver transplantation: impact and treatment of hepatitis C virus recurrence: . Current Opinion in Organ Transplantation 2006;11:599-607. [DOI: 10.1097/mot.0b013e3280106c3d] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
353 Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 2007; 13(1): 74-81 [PMID: 17206756 DOI: 10.3748/wjg.v13.i1.74] [Cited by in CrossRef: 170] [Cited by in F6Publishing: 166] [Article Influence: 12.1] [Reference Citation Analysis]
354 Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Review of Gastroenterology & Hepatology 2014;3:353-67. [DOI: 10.1586/egh.09.35] [Cited by in Crossref: 197] [Cited by in F6Publishing: 193] [Article Influence: 28.1] [Reference Citation Analysis]
355 Ramirez AG, Munoz E, Holden AE, Adeigbe RT, Suarez L. Incidence of hepatocellular carcinoma in Texas Latinos, 1995-2010: an update. PLoS One 2014;9:e99365. [PMID: 24915432 DOI: 10.1371/journal.pone.0099365] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
356 Malaguarnera M, Vacante M, Fichera R, Cappellani A, Cristaldi E, Motta M. Chromogranin A (CgA) serum level as a marker of progression in hepatocellular carcinoma (HCC) of elderly patients. Arch Gerontol Geriatr. 2010;51:81-85. [PMID: 19766330 DOI: 10.1016/j.archger.2009.08.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
357 Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: Current status. World J Radiol 2010; 2(11): 417-424 [PMID: 21179308 DOI: 10.4329/wjr.v2.i11.417] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 57] [Article Influence: 5.5] [Reference Citation Analysis]
358 Kanwal F, El-serag HB. Hepatocellular cancer care: Cost is important but only one factor of disease burden. Journal of Hepatology 2009;50:10-2. [DOI: 10.1016/j.jhep.2008.10.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
359 Xu D, Cai J, Wan ZK, Gao H, Sun Y. Pathophysiological role of prostaglandin E synthases in liver diseases. Prostaglandins Other Lipid Mediat 2021;154:106552. [PMID: 33930567 DOI: 10.1016/j.prostaglandins.2021.106552] [Reference Citation Analysis]
360 Carr BI, Kanke F, Wise M, Satomura S. Clinical Evaluation of Lens Culinaris Agglutinin-Reactive α-Fetoprotein and Des-γ-Carboxy Prothrombin in Histologically Proven Hepatocellular Carcinoma in the United States. Dig Dis Sci 2007;52:776-82. [DOI: 10.1007/s10620-006-9541-2] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 6.1] [Reference Citation Analysis]
361 Kar P. Risk factors for hepatocellular carcinoma in India. J Clin Exp Hepatol. 2014;4:S34-S42. [PMID: 25755609 DOI: 10.1016/j.jceh.2014.02.155] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
362 Choi J, Corder NL, Koduru B, Wang Y. Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma. Free Radic Biol Med 2014;72:267-84. [PMID: 24816297 DOI: 10.1016/j.freeradbiomed.2014.04.020] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
363 Konfortion J, Coupland VH, Kocher HM, Allum W, Grocock MJ, Jack RH. Time and deprivation trends in incidence of primary liver cancer subtypes in England. J Eval Clin Pract. 2014;20:498-504. [PMID: 24902884 DOI: 10.1111/jep.12188] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
364 Abdul-al HM, Guanghua Wang, Makhlouf HR, Goodman ZD. Fibrolamellar Hepatocellular Carcinoma: An Immunohistochemical Comparison With Conventional Hepatocellular Carcinoma. Int J Surg Pathol 2010;18:313-8. [DOI: 10.1177/1066896910364229] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
365 Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74. [PMID: 19330875 DOI: 10.1002/hep.22759] [Cited by in Crossref: 2134] [Cited by in F6Publishing: 1934] [Article Influence: 177.8] [Reference Citation Analysis]
366 Sersté T, Barrau V, Ozenne V, Vullierme M, Bedossa P, Farges O, Valla D, Vilgrain V, Paradis V, Degos F. Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: Role of biopsy. Hepatology 2012;55:800-6. [DOI: 10.1002/hep.24746] [Cited by in Crossref: 108] [Cited by in F6Publishing: 91] [Article Influence: 12.0] [Reference Citation Analysis]
367 Ramalho M, Matos AP, AlObaidy M, Velloni F, Altun E, Semelka RC. Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment - Part 1. Radiol Bras. 2017;50:38-47. [PMID: 28298731 DOI: 10.1590/0100-3984.2015.0132] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
368 Shaw JJ, Shah SA. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Expert Rev Gastroenterol Hepatol 2011;5:365-70. [PMID: 21651354 DOI: 10.1586/egh.11.20] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
369 Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, Gralla J, Rosen HR, Roberts JP. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl. 2012;18:1471-1478. [PMID: 23008049 DOI: 10.1002/lt.23551] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
370 Worachartcheewan A, Prachayasittikul V, Toropova AP, Toropov AA, Nantasenamat C. Large-scale structure-activity relationship study of hepatitis C virus NS5B polymerase inhibition using SMILES-based descriptors. Mol Divers 2015;19:955-64. [DOI: 10.1007/s11030-015-9614-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
371 Asim M, Sarma MP, Kar P. Etiological and molecular profile of hepatocellular cancer from India. Int J Cancer 2013;133:437-45. [PMID: 23233429 DOI: 10.1002/ijc.27993] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
372 Kozyreva ON, Chi D, Clark JW, Wang H, Theall KP, Ryan DP, Zhu AX. A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Oncologist. 2011;16:310-318. [PMID: 21349948 DOI: 10.1634/theoncologist.2010-0223] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
373 Wang L, Zhou N, Qu J, Jiang M, Zhang X. Identification of an RNA binding protein-related gene signature in hepatocellular carcinoma patients. Mol Med 2020;26:125. [PMID: 33297932 DOI: 10.1186/s10020-020-00252-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
374 Ohki T, Tateishi R, Goto E, Sato T, Masuzaki R, Imamura J, Goto T, Kanai F, Kato N, Shiina S. Influence of anti-HBc seropositivity on the risk of hepatocellular carcinoma in HCV-infected patients after adjusting for confounding factors. J Viral Hepat. 2010;17:91-97. [PMID: 19566786 DOI: 10.1111/j.1365-2893.2009.01152.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
375 Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol. 2014;184:574-583. [PMID: 24388934 DOI: 10.1016/j.ajpath.2013.10.028] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
376 El-Fattah MA, Aboelmagd M, Elhamouly M. Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study. United European Gastroenterol J 2017;5:227-35. [PMID: 28344790 DOI: 10.1177/2050640616659024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
377 Hartford SA, Luo Y, Southard TL, Min IM, Lis JT, Schimenti JC. Minichromosome maintenance helicase paralog MCM9 is dispensible for DNA replication but functions in germ-line stem cells and tumor suppression. Proc Natl Acad Sci U S A 2011;108:17702-7. [PMID: 21987787 DOI: 10.1073/pnas.1113524108] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
378 Jouve JL, Lecomte T, Bouché O, Barbier E, Khemissa Akouz F, Riachi G, Nguyen Khac E, Ollivier-Hourmand I, Debette-Gratien M, Faroux R, Villing AL, Vergniol J, Ramee JF, Bronowicki JP, Seitz JF, Legoux JL, Denis J, Manfredi S, Phelip JM; PRODIGE-11 investigators/collaborators. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. J Hepatol 2019;71:516-22. [PMID: 31125576 DOI: 10.1016/j.jhep.2019.04.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
379 Artinyan A, Mailey B, Sanchez-Luege N, Khalili J, Sun CL, Bhatia S, Wagman LD, Nissen N, Colquhoun SD, Kim J. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer. 2010;116:1367-1377. [PMID: 20101732 DOI: 10.1002/cncr.24817] [Cited by in Crossref: 150] [Cited by in F6Publishing: 149] [Article Influence: 13.6] [Reference Citation Analysis]
380 Barr DC, Hussain HK. MR Imaging in Cirrhosis and Hepatocellular Carcinoma. Magnetic Resonance Imaging Clinics of North America 2014;22:315-35. [DOI: 10.1016/j.mric.2014.04.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
381 Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, Stoeltzing O, Warnecke C, Schölmerich J, Oefner PJ, Kreutz M, Bosserhoff AK, Hellerbrand C. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol 2009;174:1544-52. [PMID: 19286567 DOI: 10.2353/ajpath.2009.080596] [Cited by in Crossref: 179] [Cited by in F6Publishing: 181] [Article Influence: 14.9] [Reference Citation Analysis]
382 Piscaglia F, Bolondi L. Recent advances in the diagnosis of hepatocellular carcinoma. Hepatology Research 2007;37:S178-92. [DOI: 10.1111/j.1872-034x.2007.00183.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
383 Chang M. Hepatitis B Virus and Cancer Prevention. In: Senn H, Otto F, editors. Clinical Cancer Prevention. Berlin: Springer Berlin Heidelberg; 2011. pp. 75-84. [DOI: 10.1007/978-3-642-10858-7_6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
384 Sasaki S, Ishida T, Toyota M, Ota A, Suzuki H, Takaoka A, Yasui H, Yamamoto H, Takagi H, Maeda M, Seito T, Tsujisaki M, Shinomura Y, Imai K. Interferon-α/β and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo. PLoS One 2011;6:e19618. [PMID: 21573021 DOI: 10.1371/journal.pone.0019618] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
385 Yu JQ, Yin Y, Lei JC, Zhang XQ, Chen W, Ding CL, Wu S, He XY, Liu YW, Zou GL. Activation of apoptosis by ethyl acetate fraction of ethanol extract of Dianthus superbus in HepG2 cell line. Cancer Epidemiol 2012;36:e40-5. [PMID: 21959229 DOI: 10.1016/j.canep.2011.09.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
386 Purcell Y, Copin P, Paulatto L, Pommier R, Vilgrain V, Ronot M. Hepatocellular carcinoma surveillance: Eastern and Western perspectives. Ultrasonography 2019;38:191-9. [PMID: 30690962 DOI: 10.14366/usg.18043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
387 Liu TQ, Fan J, Zhou L, Zheng SS. Effects of suppressing glucose transporter-1 by an antisense oligodeoxynucleotide on the growth of human hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int 2011;10:72-7. [PMID: 21269938 DOI: 10.1016/s1499-3872(11)60010-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
388 Wan DW, Tzimas D, Smith JA, Kim S, Araujo J, David R, Lobach I, Sarpel U. Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States. Am J Gastroenterol. 2011;106:1994-2000. [PMID: 21912436 DOI: 10.1038/ajg.2011.302] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
389 Yang Y, Zhang J, Wu T, Xu X, Cao G, Li H, Chen X. Histone deacetylase 2 regulates the doxorubicin (Dox) resistance of hepatocarcinoma cells and transcription of ABCB1. Life Sci 2019;216:200-6. [PMID: 30465789 DOI: 10.1016/j.lfs.2018.11.043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
390 Cao M, Xu Y, Youn JI, Cabrera R, Zhang X, Gabrilovich D, Nelson DR, Liu C. Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab Invest. 2011;91:598-608. [PMID: 21321535 DOI: 10.1038/labinvest.2010.205] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 7.9] [Reference Citation Analysis]
391 Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, Bigger CB. Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 2006;43:961-72. [PMID: 16628626 DOI: 10.1002/hep.21167] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 5.7] [Reference Citation Analysis]
392 Hu J, Liu K, Luo J. HIV-HBV and HIV-HCV Coinfection and Liver Cancer Development. Cancer Treat Res 2019;177:231-50. [PMID: 30523627 DOI: 10.1007/978-3-030-03502-0_9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
393 Berenguer M. Management of Hepatitis C Virus in the Transplant Patient. Clinics in Liver Disease 2007;11:355-76. [DOI: 10.1016/j.cld.2007.04.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
394 Singal AG, Marrero JA. Recent advances in the treatment of hepatocellular carcinoma: . Current Opinion in Gastroenterology 2010;26:189-95. [DOI: 10.1097/mog.0b013e3283383ca5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
395 Furlan A, Almusa O, Yu RK, Sagreiya H, Borhani AA, Bae KT, Marsh JW. A radiogenomic analysis of hepatocellular carcinoma: association between fractional allelic imbalance rate index and the liver imaging reporting and data system (LI-RADS) categories and features. Br J Radiol 2018;91:20170962. [PMID: 29565672 DOI: 10.1259/bjr.20170962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
396 Goto E, Masuzaki R, Tateishi R, Kondo Y, Imamura J, Goto T, Ikeda H, Akahane M, Shiina S, Omata M, Yoshida H, Koike K. Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma. J Gastroenterol 2012;47:477-85. [PMID: 22200940 DOI: 10.1007/s00535-011-0512-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
397 Yang ZF, Poon RT. Vascular changes in hepatocellular carcinoma. Anat Rec (Hoboken). 2008;291:721-734. [PMID: 18484619 DOI: 10.1002/ar.20668] [Cited by in Crossref: 112] [Cited by in F6Publishing: 111] [Article Influence: 8.6] [Reference Citation Analysis]
398 Goodman ZD. Neoplasms of the liver. Mod Pathol. 2007;20 Suppl 1:S49-S60. [PMID: 17486052 DOI: 10.1038/modpathol.3800682] [Cited by in Crossref: 77] [Cited by in F6Publishing: 61] [Article Influence: 5.5] [Reference Citation Analysis]
399 Woo HG, Wang XW, Budhu A, Kim YH, Kwon SM, Tang ZY, Sun Z, Harris CC, Thorgeirsson SS. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology. 2011;140:1063-1070. [PMID: 21094160 DOI: 10.1053/j.gastro.2010.11.034] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 7.5] [Reference Citation Analysis]
400 Liu J, Mittendorf T, von der Schulenburg JM. A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Invest 2010;28:312-22. [PMID: 19863345 DOI: 10.3109/07357900903287022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
401 Spangenberg HC, Thimme R, Blum HE. Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008;2:425-33. [PMID: 19072390 DOI: 10.1586/17474124.2.3.425] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
402 Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103:914-921. [PMID: 18177453 DOI: 10.1111/j.1572-0241.2007.01712.x] [Cited by in Crossref: 258] [Cited by in F6Publishing: 267] [Article Influence: 19.8] [Reference Citation Analysis]
403 El-Bendary M, Elalfy H, Zalata K. Predictors of hepatocyte proliferative activity in chronic hepatitis B and C vs. steatohepatitis as assessed by the monoclonal antibody MIB1-Ki-67. Arab J Gastroenterol 2011;12:119-24. [PMID: 22055588 DOI: 10.1016/j.ajg.2011.07.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
404 Cougot D, Neuveut C, Buendia MA. HBV induced carcinogenesis. J Clin Virol. 2005;34 Suppl 1:S75-S78. [PMID: 16461228 DOI: 10.1016/s1386-6532(05)80014-9] [Cited by in Crossref: 115] [Cited by in F6Publishing: 64] [Article Influence: 7.7] [Reference Citation Analysis]
405 Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502-509; discussion 509. [PMID: 17717454 DOI: 10.1097/sla.0b013e318148c704] [Cited by in Crossref: 331] [Cited by in F6Publishing: 101] [Article Influence: 23.6] [Reference Citation Analysis]
406 Baek HJ, Lim SC, Kitisin K, Jogunoori W, Tang Y, Marshall MB, Mishra B, Kim TH, Cho KH, Kim SS. Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology. 2008;48:1128-1137. [PMID: 18704924 DOI: 10.1002/hep.22460] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
407 Méndez-sánchez; N, Vásquez-fernández; F, Zamora-valdés; D, Uribe M. Sorafenib, a systemic therapy for hepatocellular carcinoma. Annals of Hepatology 2008;7:46-51. [DOI: 10.1016/s1665-2681(19)31886-1] [Cited by in Crossref: 23] [Article Influence: 1.8] [Reference Citation Analysis]
408 Abbas R, Kombu RS, Ibarra RA, Goyal KK, Brunengraber H, Sanabria JR. The dynamics of glutathione species and ophthalmate concentrations in plasma from the VX2 rabbit model of secondary liver tumors. HPB Surg 2011;2011:709052. [PMID: 21350723 DOI: 10.1155/2011/709052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
409 Wilson TC, Kirby PA. A 50-year-old man with back pain and a sellar mass. Metastatic hepatocellular carcinoma. Brain Pathol 2013;23:365-6. [PMID: 23587145 DOI: 10.1111/bpa.12053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
410 Cunningham SC, Choti MA, Bellavance EC, Pawlik TM. Palliation of hepatic tumors. Surgical Oncology 2007;16:277-91. [DOI: 10.1016/j.suronc.2007.08.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
411 Baillargeon J, Snyder N, Soloway RD, Paar D, Baillargeon G, Spaulding AC, Pollock BH, Arcari CM, Williams BA, Raimer BG. Hepatocellular carcinoma prevalence and mortality in a male state prison population. Public Health Rep 2009;124:120-6. [PMID: 19413034 DOI: 10.1177/003335490912400115] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
412 Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol 2013;35:111-20. [DOI: 10.1007/s00281-012-0330-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
413 Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 2008;47:1557-66. [PMID: 18318443 DOI: 10.1002/hep.22201] [Cited by in Crossref: 187] [Cited by in F6Publishing: 182] [Article Influence: 14.4] [Reference Citation Analysis]
414 Bhat M, Chaiteerakij R, Harmsen WS, Schleck CD, Yang JD, Giama NH, Therneau TM, Gores GJ, Roberts LR. Metformin does not improve survival in patients with hepatocellular carcinoma. World J Gastroenterol 2014; 20(42): 15750-15755 [PMID: 25400459 DOI: 10.3748/wjg.v20.i42.15750] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
415 Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014;161:170-80. [PMID: 25089861 DOI: 10.7326/M14-0095] [Cited by in Crossref: 107] [Cited by in F6Publishing: 58] [Article Influence: 15.3] [Reference Citation Analysis]
416 Jiang K, Centeno BA. Primary Liver Cancers, Part 2: Progression Pathways and Carcinogenesis. Cancer Control 2018;25:1073274817744658. [PMID: 29353494 DOI: 10.1177/1073274817744658] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
417 Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis. Eur Radiol 2011;21:1233-42. [DOI: 10.1007/s00330-010-2030-1] [Cited by in Crossref: 138] [Cited by in F6Publishing: 128] [Article Influence: 13.8] [Reference Citation Analysis]
418 Bishayee A. The role of inflammation and liver cancer. Adv Exp Med Biol. 2014;816:401-435. [PMID: 24818732 DOI: 10.1007/978-3-0348-0837-8_16] [Cited by in Crossref: 130] [Cited by in F6Publishing: 123] [Article Influence: 18.6] [Reference Citation Analysis]
419 Khalil MI, Ibrahim MM, El-Gaaly GA, Sultan AS. Trigonella foenum (Fenugreek) Induced Apoptosis in Hepatocellular Carcinoma Cell Line, HepG2, Mediated by Upregulation of p53 and Proliferating Cell Nuclear Antigen. Biomed Res Int 2015;2015:914645. [PMID: 26557712 DOI: 10.1155/2015/914645] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
420 Borena W, Strohmaier S, Lukanova A, Bjørge T, Lindkvist B, Hallmans G, Edlinger M, Stocks T, Nagel G, Manjer J, Engeland A, Selmer R, Häggström C, Tretli S, Concin H, Jonsson H, Stattin P, Ulmer H. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 2012;131:193-200. [PMID: 21805476 DOI: 10.1002/ijc.26338] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 8.9] [Reference Citation Analysis]
421 Zheng S, Li X, Zhang Y, Xie Q, Wong YS, Zheng W, Chen T. PEG-nanolized ultrasmall selenium nanoparticles overcome drug resistance in hepatocellular carcinoma HepG2 cells through induction of mitochondria dysfunction. Int J Nanomedicine 2012;7:3939-49. [PMID: 22915845 DOI: 10.2147/IJN.S30940] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
422 Gunduz F, Aboulnasr FM, Chandra PK, Hazari S, Poat B, Baker DP, Balart LA, Dash S. Free fatty acids induce ER stress and block antiviral activity of interferon alpha against hepatitis C virus in cell culture. Virol J 2012;9:143. [PMID: 22863531 DOI: 10.1186/1743-422X-9-143] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
423 Cho Y, Park MJ, Kim K, Park JY, Kim J, Kim W, Yoon JH. Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E472. [PMID: 31940813 DOI: 10.3390/ijms21020472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
424 Zhou M, Yang H, Learned RM, Tian H, Ling L. Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. Nat Commun 2017;8:15433. [PMID: 28508871 DOI: 10.1038/ncomms15433] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 17.3] [Reference Citation Analysis]
425 Hazari S, Taylor L, Haque S, Garry RF, Florman S, Luftig R, Regenstein F, Dash S. Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. Virol J 2007;4:89. [PMID: 17877826 DOI: 10.1186/1743-422X-4-89] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
426 Asrani SK, Hall L, Hagan M, Sharma S, Yeramaneni S, Trotter J, Talwalkar J, Kanwal F. Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. Am J Gastroenterol 2019;114:98-106. [PMID: 30333543 DOI: 10.1038/s41395-018-0365-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
427 Siddiqui FA, Ehrinpreis MN, Janisse J, Dhar R, May E, Mutchnick MG. Demographics of a large cohort of urban chronic hepatitis C patients. Hepatol Int 2008;2:376-81. [PMID: 19669268 DOI: 10.1007/s12072-008-9086-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
428 Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 2013;119:3334-42. [PMID: 23821538 DOI: 10.1002/cncr.28209] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
429 Kumthekar A, Shull S, Lovejoy TI, Morasco BJ, Chang M, Barton J. Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis. Int J Rheum Dis 2019;22:592-8. [PMID: 30729702 DOI: 10.1111/1756-185X.13479] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
430 Ni Q, Chen J, Li X, Xu X, Zhang N, Zhou A, Zhou B, Lu Q, Chen Z. Expression of OTUB1 in hepatocellular carcinoma and its effects on HCC cell migration and invasion. Acta Biochim Biophys Sin (Shanghai) 2017;49:680-8. [PMID: 28575188 DOI: 10.1093/abbs/gmx056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
431 Herman P, Perini MV, Coelho FF, Kruger JA, Lupinacci RM, Fonseca GM, Lopes Fde L, Cecconello I. Laparoscopic resection of hepatocellular carcinoma: when, why, and how? A single-center experience. J Laparoendosc Adv Surg Tech A. 2014;24:223-228. [PMID: 24568364 DOI: 10.1089/lap.2013.0502] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
432 Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson MS, Georgiades C, Geschwind JF. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol. 2007;18:95-101. [PMID: 17296709 DOI: 10.1016/j.jvir.2006.10.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
433 Bishayee A, Bhatia D, Thoppil RJ, Darvesh AS, Nevo E, Lansky EP. Pomegranate-mediated chemoprevention of experimental hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms. Carcinogenesis 2011;32:888-96. [PMID: 21389260 DOI: 10.1093/carcin/bgr045] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 7.3] [Reference Citation Analysis]
434 Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 2006;25:3801-9. [PMID: 16799621 DOI: 10.1038/sj.onc.1209561] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 5.2] [Reference Citation Analysis]
435 Hsu A, Lai CL, Yuen MF. Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. Curr Hepat Rep. 2011;10:106-111. [PMID: 21654908 DOI: 10.1007/s11901-011-0094-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
436 Friedman SL. Focus. J Hepatol 2014;60:1-2. [PMID: 24121095 DOI: 10.1016/j.jhep.2013.10.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
437 Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene. 2006;25:3771-3777. [PMID: 16799618 DOI: 10.1038/sj.onc.1209560] [Cited by in Crossref: 103] [Cited by in F6Publishing: 100] [Article Influence: 6.9] [Reference Citation Analysis]
438 Méndez-sánchez N, Villa AR, Vázquez-elizondo G, Ponciano-rodrí G, Uribe M. Mortality trends for liver cancer in Mexico from 2000 to 2006. Annals of Hepatology 2008;7:226-9. [DOI: 10.1016/s1665-2681(19)31852-6] [Cited by in Crossref: 23] [Article Influence: 1.8] [Reference Citation Analysis]
439 Chhatwal J, Wang X, Ayer T, Kabiri M, Chung RT, Hur C, Donohue JM, Roberts MS, Kanwal F. Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. Hepatology. 2016;64:1442-1450. [PMID: 27015107 DOI: 10.1002/hep.28571] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 20.4] [Reference Citation Analysis]
440 Paprottka KJ, Lehner S, Fendler WP, Ilhan H, Rominger A, Sommer W, Clevert DA, Op den Winkel M, Heinemann V, Paprottka PM. Reduced Periprocedural Analgesia After Replacement of Water for Injection with Glucose 5% Solution as the Infusion Medium for 90Y-Resin Microspheres. J Nucl Med 2016;57:1679-84. [PMID: 27261516 DOI: 10.2967/jnumed.115.170779] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
441 Theodoropoulos J, Brooks A. Inconsistency in the Management of Patients with Hepatocellular Carcinoma: The Need for a Strict Protocol. The American Surgeon 2011;77:207-14. [DOI: 10.1177/000313481107700223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
442 Buch SC, Kondragunta V, Branch RA, Carr BI. Gender-based outcomes differences in unresectable hepatocellular carcinoma. Hepatol Int. 2008;2:95-101. [PMID: 19669284 DOI: 10.1007/s12072-007-9041-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
443 Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47. [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x] [Cited by in Crossref: 454] [Cited by in F6Publishing: 385] [Article Influence: 37.8] [Reference Citation Analysis]
444 Liu Y, Li Y, Guo F, Dai M, Wang J, Hu J, Li G. Identification of HTA as a novel-specific marker for human hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:1187-92. [PMID: 20130911 DOI: 10.1007/s00432-010-0767-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
445 Prajapati HJ, Xing M, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, Kim HS. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. AJR Am J Roentgenol. 2014;203:W706-W714. [PMID: 25415737 DOI: 10.2214/ajr.13.12308] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
446 Pahwa A, Beckett K, Channual S, Tan N, Lu DS, Raman SS. Efficacy of the American Association for the Study of Liver Disease and Barcelona criteria for the diagnosis of hepatocellular carcinoma. Abdom Imaging 2014;39:753-60. [DOI: 10.1007/s00261-014-0118-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
447 Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis. 2014;58:40-49. [PMID: 24065331 DOI: 10.1093/cid/cit642] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.8] [Reference Citation Analysis]
448 Lin YC, Lian IB, Kor CT, Chang CC, Su PY, Chang WT, Liang YF, Su WW, Soon MS. Association between soil heavy metals and fatty liver disease in men in Taiwan: a cross sectional study. BMJ Open 2017;7:e014215. [PMID: 28115335 DOI: 10.1136/bmjopen-2016-014215] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
449 Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145:375-382.e1-2. [PMID: 23583430 DOI: 10.1053/j.gastro.2013.04.005] [Cited by in Crossref: 172] [Cited by in F6Publishing: 161] [Article Influence: 21.5] [Reference Citation Analysis]
450 Khachatoorian R, French SW. Chaperones in hepatitis C virus infection. World J Hepatol 2016; 8(1): 9-35 [PMID: 26783419 DOI: 10.4254/wjh.v8.i1.9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
451 Mitra A, Satelli A, Xia X, Cutrera J, Mishra L, Li S. Cell-surface Vimentin: A mislocalized protein for isolating csVimentin(+) CD133(-) novel stem-like hepatocellular carcinoma cells expressing EMT markers. Int J Cancer. 2015;137:491-496. [PMID: 25487874 DOI: 10.1002/ijc.29382] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 6.6] [Reference Citation Analysis]
452 Zhang W, Jiang R, Hou J, Sun B. Clinicopathological features and prognostic factors of young patients with surgically treated liver cancer. Medicine (Baltimore) 2015;94:e684. [PMID: 25816040 DOI: 10.1097/MD.0000000000000684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
453 Bishayee A, Thoppil RJ, Mandal A, Darvesh AS, Ohanyan V, Meszaros JG, Háznagy-radnai E, Hohmann J, Bhatia D. Black currant phytoconstituents exert chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis by suppression of the inflammatory response: BLACK CURRANT AND HEPATOCARCINOGENESIS. Mol Carcinog 2013;52:304-17. [DOI: 10.1002/mc.21860] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
454 Sarpel U, Suprun M, Sofianou A, Berger Y, Tedjasukmana A, Sekendiz Z, Bagiella E, Schwartz ME. Disentangling the effects of race and socioeconomic factors on liver transplantation rates for hepatocellular carcinoma. Clin Transplant 2016;30:714-21. [PMID: 27027869 DOI: 10.1111/ctr.12739] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
455 Schreibman IR, Bejarano P, Martinez EJ, Regev A. Very late recurrence of hepatocellular carcinoma after liver transplantation: case report and literature review. Transplant Proc. 2006;38:3140-3143. [PMID: 17112921 DOI: 10.1016/j.transproceed.2006.08.095] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
456 Shoreibah MG, Bloomer JR, McGuire BM, Massoud OI. Surveillance for hepatocellular carcinoma: evidence, guidelines and utilization. Am J Med Sci. 2014;347:415-419. [PMID: 24759379 DOI: 10.1097/maj.0000000000000200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
457 Ohba T, Yano T, Yoshida T, Kawano D, Tsukamoto S, Shoji F, Taketomi A, Saitsu H, Takeo S, Maehara Y. Results of a surgical resection of pulmonary metastasis from hepatocellular carcinoma: prognostic impact of the preoperative serum alpha-fetoprotein level. Surg Today. 2012;42:526-531. [PMID: 22173647 DOI: 10.1007/s00595-011-0090-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
458 Göbel T, Schadewaldt-Tümmers J, Greiner L, Poremba C, Häussinger D, Erhardt A. Transient elastography improves detection of liver cirrhosis compared to routine screening tests. World J Gastroenterol 2015; 21(3): 953-960 [PMID: 25624730 DOI: 10.3748/wjg.v21.i3.953] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
459 Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer. 2009;9:324. [PMID: 19744348 DOI: 10.1186/1471-2407-9-324] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
460 Kitisin K, Ganesan N, Tang Y, Jogunoori W, Volpe EA, Kim SS, Katuri V, Kallakury B, Pishvaian M, Albanese C. Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene. 2007;26:7103-7110. [PMID: 17546056 DOI: 10.1038/sj.onc.1210513] [Cited by in Crossref: 84] [Cited by in F6Publishing: 90] [Article Influence: 6.0] [Reference Citation Analysis]
461 Jia YL, Shi L, Zhou JN, Fu CJ, Chen L, Yuan HF, Wang YF, Yan XL, Xu YC, Zeng Q. Epimorphin promotes human hepatocellular carcinoma invasion and metastasis through activation of focal adhesion kinase/extracellular signal-regulated kinase/matrix metalloproteinase-9 axis. Hepatology. 2011;54:1808-1818. [PMID: 22045676 DOI: 10.1002/hep.24562] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 6.6] [Reference Citation Analysis]
462 McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2010;14:461-476. [PMID: 20638025 DOI: 10.1016/j.cld.2010.05.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
463 Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol. 2009;193:1044-1052. [PMID: 19770328 DOI: 10.2214/ajr.08.1461] [Cited by in Crossref: 137] [Cited by in F6Publishing: 46] [Article Influence: 11.4] [Reference Citation Analysis]
464 Giannelli G, Marinosci F, Trerotoli P, Volpe A, Quaranta M, Dentico P, Antonaci S. SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int J Cancer. 2005;117:506-509. [PMID: 15906357 DOI: 10.1002/ijc.21189] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
465 Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, Jeong W, Lee SS, Park ES, Kaseb A. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med. 2014;11:e1001770. [PMID: 25536056 DOI: 10.1371/journal.pmed.1001770] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 8.3] [Reference Citation Analysis]
466 Jin J, You H, Yu B, Deng Y, Tang N, Yao G, Shu H, Yang S, Qin W. Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas. Biochem Biophys Res Commun. 2009;379:86-91. [PMID: 19100240 DOI: 10.1016/j.bbrc.2008.12.022] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
467 Chen PH, Lin YC, Tu HP, Chiang SL, Ko AM, Hsu CL, Chang YF, Ko YC. Important prognostic factors for the long-term survival of subjects with primary liver cancer in Taiwan: a hyperendemic area. Eur J Cancer 2007;43:1076-84. [PMID: 17329095 DOI: 10.1016/j.ejca.2007.01.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
468 Hlady RA, Tiedemann RL, Puszyk W, Zendejas I, Roberts LR, Choi JH, Liu C, Robertson KD. Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. Oncotarget 2014;5:9425-43. [PMID: 25294808 DOI: 10.18632/oncotarget.2444] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 8.7] [Reference Citation Analysis]
469 Farnam JL, Smith BC, Johnson BR, Estrada R, Edelman TL, Farah R, Cressman EN. Thermochemical ablation in an ex-vivo porcine liver model using acetic acid and sodium hydroxide: proof of concept. J Vasc Interv Radiol 2010;21:1573-8. [PMID: 20801679 DOI: 10.1016/j.jvir.2010.06.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
470 Caillot F, Daveau R, Daveau M, Lubrano J, Saint-auret G, Hiron M, Goria O, Scotte M, Francois A, Salier J. Down-regulated expression of the TSAP6 protein in liver is associated with a transition from cirrhosis to hepatocellular carcinoma. Histopathology 2009;54:319-27. [DOI: 10.1111/j.1365-2559.2009.03224.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
471 Diehl AM, Choi SS. The Liver in Type 2 Diabetes Mellitus. In: Feinglos MN, Bethel MA, editors. Type 2 Diabetes Mellitus. Totowa: Humana Press; 2008. pp. 351-64. [DOI: 10.1007/978-1-60327-043-4_21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
472 Duvoux C, Samuel D. La transplantation hépatique. Gastroentérologie Clinique et Biologique 2009;33:868-81. [DOI: 10.1016/j.gcb.2009.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
473 Ha BY, Ahmed A, Sze DY, Razavi MK, Simpson N, Keeffe EB, Nguyen MH. Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion. Aliment Pharmacol Ther 2007;26:839-46. [PMID: 17767468 DOI: 10.1111/j.1365-2036.2007.03424.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
474 Monga SP. Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol. 2011;43:1021-1029. [PMID: 19747566 DOI: 10.1016/j.biocel.2009.09.001] [Cited by in Crossref: 100] [Cited by in F6Publishing: 108] [Article Influence: 8.3] [Reference Citation Analysis]
475 Fusco M, Girardi E, Piselli P, Palombino R, Polesel J, Maione C, Scognamiglio P, Pisanti FA, Solmone M, Di Cicco P. Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer. 2008;44:847-853. [PMID: 18313290 DOI: 10.1016/j.ejca.2008.01.025] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
476 Dyer Z, Peltekian K, Veldhuyzen Van Zanten S. Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther 2005;22:17-22. [DOI: 10.1111/j.1365-2036.2005.02504.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
477 Park MS, Han K, Kim SU. Non-invasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease. Expert Review of Gastroenterology & Hepatology 2014;8:501-11. [DOI: 10.1586/17474124.2014.898563] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
478 Di Bisceglie AM, Befeler AS. Diagnostic and therapeutic approach to hepatocellular carcinoma in the USA. Hepatol Res 2007;37 Suppl 2:S251-3. [PMID: 17877490 DOI: 10.1111/j.1872-034X.2007.00192.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
479 Diaz KE, Schiano TD. Evaluation and Management of Cirrhotic Patients Undergoing Elective Surgery. Curr Gastroenterol Rep 2019;21:32. [PMID: 31203525 DOI: 10.1007/s11894-019-0700-y] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
480 Gruden G, Carucci P, Lolli V, Cosso L, Dellavalle E, Rolle E, Cantamessa A, Pinach S, Abate ML, Campra D. Serum heat shock protein 27 levels in patients with hepatocellular carcinoma. Cell Stress Chaperones. 2013;18:235-241. [PMID: 23073653 DOI: 10.1007/s12192-012-0377-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
481 Amann T, Bataille F, Spruss T, Mühlbauer M, Gäbele E, Schölmerich J, Kiefer P, Bosserhoff AK, Hellerbrand C. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci. 2009;100:646-653. [PMID: 19175606 DOI: 10.1111/j.1349-7006.2009.01087.x] [Cited by in Crossref: 171] [Cited by in F6Publishing: 163] [Article Influence: 14.3] [Reference Citation Analysis]
482 Masuda T, Miyoshi E. Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics. Clin Chem Lab Med 2011;49:959-66. [PMID: 21428856 DOI: 10.1515/CCLM.2011.152] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
483 Matsuo N, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Tanaka S, Nishina S, Nakanishi Y, Uemura M, Takaki A, Nakamura S, Kobayashi Y, Nouso K, Yagi T, Yamamoto K. Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer 2009;9:240. [PMID: 19615090 DOI: 10.1186/1471-2407-9-240] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 7.1] [Reference Citation Analysis]
484 Ryu SH, Jang MK, Kim WJ, Lee D, Chung YH. Metastatic tumor antigen in hepatocellular carcinoma: golden roads toward personalized medicine. Cancer Metastasis Rev 2014;33:965-80. [PMID: 25325987 DOI: 10.1007/s10555-014-9522-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
485 Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol. 2007;46:645-654. [PMID: 17196295 DOI: 10.1016/j.jhep.2006.10.012] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 4.3] [Reference Citation Analysis]
486 Shivappa N, Hébert JR, Polesel J, Zucchetto A, Crispo A, Montella M, Franceschi S, Rossi M, La Vecchia C, Serraino D. Inflammatory potential of diet and risk for hepatocellular cancer in a case-control study from Italy. Br J Nutr 2016;115:324-31. [PMID: 26556602 DOI: 10.1017/S0007114515004419] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
487 Ertle J, Dechêne A, Sowa J, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn W, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis: Absence of Cirrhosis in NASH-Derived HCC. Int J Cancer 2011;128:2436-43. [DOI: 10.1002/ijc.25797] [Cited by in Crossref: 290] [Cited by in F6Publishing: 279] [Article Influence: 29.0] [Reference Citation Analysis]
488 Beste LA, Ioannou GN, Yang Y, Chang MF, Ross D, Dominitz JA. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol 2015;13:172-9. [PMID: 24813175 DOI: 10.1016/j.cgh.2014.04.033] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
489 Loomba R, Yang HI, Su J, Brenner D, Barrett-Connor E, Iloeje U, Chen CJ. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol. 2013;177:333-342. [PMID: 23355498 DOI: 10.1093/aje/kws252] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 13.3] [Reference Citation Analysis]
490 Gervais DA, Goldberg SN, Brown DB, Soulen MC, Millward SF, Rajan DK; Interventional Oncology Task Force and Standards Division, Society of Interventional Radiology. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol 2009;20:3-8. [PMID: 18948025 DOI: 10.1016/j.jvir.2008.09.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
491 Mondal A, Guria T, Maity TK, Bishayee A. A Novel Tetraenoic Fatty Acid Isolated from Amaranthus spinosus Inhibits Proliferation and Induces Apoptosis of Human Liver Cancer Cells. Int J Mol Sci 2016;17:E1604. [PMID: 27669220 DOI: 10.3390/ijms17101604] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
492 Cressman ENK, Tseng H, Talaie R, Henderson BM. A new heat source for thermochemical ablation based on redox chemistry: Initial studies using permanganate. International Journal of Hyperthermia 2010;26:327-37. [DOI: 10.3109/02656731003614516] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
493 Yip B, Wantuck JM, Kim LH, Wong RJ, Ahmed A, Garcia G, Nguyen MH. Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma. Dig Dis Sci 2014;59:192-200. [PMID: 24282055 DOI: 10.1007/s10620-013-2948-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
494 Foster J, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Ann Surg Oncol. 2007;14:752-758. [PMID: 17146741 DOI: 10.1245/s10434-006-9123-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
495 Ware MJ, Curtis LT, Wu M, Ho JC, Corr SJ, Curley SA, Godin B, Frieboes HB. Pancreatic adenocarcinoma response to chemotherapy enhanced with non-invasive radio frequency evaluated via an integrated experimental/computational approach. Sci Rep 2017;7:3437. [PMID: 28611425 DOI: 10.1038/s41598-017-03040-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
496 Cheung TC, Coppieters K, Sanjo H, Oborne LM, Norris PS, Coddington A, Granger SW, Elewaut D, Ware CF. Polymorphic variants of LIGHT (TNF superfamily-14) alter receptor avidity and bioavailability. J Immunol 2010;185:1949-58. [PMID: 20592286 DOI: 10.4049/jimmunol.1001159] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
497 Carrilho FJ, Kikuchi L, Branco F, Goncalves CS, Mattos AA; Brazilian HCC Study Group. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Clinics (Sao Paulo). 2010;65:1285-1290. [PMID: 21340216 DOI: 10.1590/s1807-59322010001200010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
498 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.1007/bf03260065] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
499 Huang G, Li S, Zhang Y, Zhou X, Chen W. Vicenin-2 is a novel inhibitor of STAT3 signaling pathway in human hepatocellular carcinoma. Journal of Functional Foods 2020;69:103921. [DOI: 10.1016/j.jff.2020.103921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
500 Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13:153-166. [PMID: 18242515 DOI: 10.1016/j.ccr.2008.01.013] [Cited by in Crossref: 835] [Cited by in F6Publishing: 775] [Article Influence: 64.2] [Reference Citation Analysis]
501 Kitisin K, Packiam V, Steel J, Humar A, Gamblin TC, Geller DA, Marsh JW, Tsung A. Presentation and outcomes of hepatocellular carcinoma patients at a western centre. HPB (Oxford) 2011;13:712-22. [PMID: 21929672 DOI: 10.1111/j.1477-2574.2011.00362.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
502 Zhang HK, Pan K, Wang H, Weng DS, Song HF, Zhou J, Huang W, Li JJ, Chen MS, Xia JC. Decreased expression of ING2 gene and its clinicopathological significance in hepatocellular carcinoma. Cancer Lett. 2008;261:183-192. [PMID: 18160212 DOI: 10.1016/j.canlet.2007.11.019] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
503 Hennig M, Yip-Schneider MT, Wentz S, Wu H, Hekmatyar SK, Klein P, Bansal N, Schmidt CM. Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems. Hepatology 2010;51:1218-25. [PMID: 20112426 DOI: 10.1002/hep.23470] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
504 Kim JH, Kim MN, Han K, Kim SU. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. Liver Int 2015;35:1103-15. [DOI: 10.1111/liv.12628] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
505 Xuan SY, Xin YN, Chen H, Shi GJ, Guan HS, Li Y. Significance of hepatitis B virus surface antigen, hepatitis C virus expression in hepatocellular carcinoma and pericarcinomatous tissues. World J Gastroenterol 2007; 13(12): 1870-1874 [PMID: 17465484 DOI: 10.3748/wjg.v13.i12.1870] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
506 Shawky MA, Mohammed AQ, Hassan AM, Ali BH, Moustafa HM. Insulin resistance in nondiabetic Egyptian patients with chronic hepatitis C virus. Rev Gastroenterol Mex (Engl Ed) 2020;85:173-9. [PMID: 31784195 DOI: 10.1016/j.rgmx.2019.05.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
507 Zou SW, Ai KX, Wang ZG, Yuan Z, Yan J, Zheng Q. The role of Med19 in the proliferation and tumorigenesis of human hepatocellular carcinoma cells. Acta Pharmacol Sin 2011;32:354-60. [PMID: 21372827 DOI: 10.1038/aps.2010.223] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
508 Aberra FB, Essenmacher M, Fisher N, Volk ML. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci. 2013;58:1157-1160. [PMID: 23111632 DOI: 10.1007/s10620-012-2461-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
509 Schiano TD. Clinical Management of Hepatic Encephalopathy. Pharmacotherapy 2010;30:10S-5S. [DOI: 10.1592/phco.30.pt2.10s] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
510 Brady CW, Smith AD, Stechuchak KM, Coffman CJ, Tuttle-newhall JE, Provenzale D, Muir AJ. Frequency and predictors ofde novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era. Liver Transpl 2008;14:228-34. [DOI: 10.1002/lt.21346] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
511 Wu CC, Yang SF, Chen WT, Tsai HP, Luo CW, Chai CY, Yin HL. Absence of CD66a expression is associated with high microvessel density and high histologic grade in hepatocellular carcinoma. Kaohsiung J Med Sci 2016;32:306-12. [PMID: 27377843 DOI: 10.1016/j.kjms.2016.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
512 Takayasu K. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective. Oncology. 2013;84 Suppl 1:28-33. [PMID: 23428855 DOI: 10.1159/000345886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
513 Liu P, Li Y, Sun C. Correlations of Serum Hepatitis C Virus RNA and Alanine Transaminase With Liver Histopathological Changes in Patients With Chronic Hepatitis C. Lab Med 2009;40:167-9. [DOI: 10.1309/lm5xqbwg0qmlnnpc] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
514 Tu Z, Bozorgzadeh A, Pierce RH, Kurtis J, Crispe IN, Orloff MS. TLR-dependent cross talk between human Kupffer cells and NK cells. J Exp Med. 2008;205:233-244. [PMID: 18195076 DOI: 10.1084/jem.20072195] [Cited by in Crossref: 150] [Cited by in F6Publishing: 155] [Article Influence: 11.5] [Reference Citation Analysis]
515 Dai Y, Li C, Wen TF, Yan LN. Comparison of liver resection and transplantation for Child-pugh A cirrhotic patient with very early hepatocellular carcinoma and portal hypertension. Pak J Med Sci. 2014;30:996-1000. [PMID: 25225514 DOI: 10.12669/pjms.305.5038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
516 Barakat O, Wood RP, Ozaki CF, Ankoma-Sey V, Galati J, Skolkin M, Toombs B, Round M, Moore W, Mieles L. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl. 2010;16:289-299. [PMID: 20209588 DOI: 10.1002/lt.21994] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 5.3] [Reference Citation Analysis]
517 Colak D, Chishti MA, Al-Bakheet AB, Al-Qahtani A, Shoukri MM, Goyns MH, Ozand PT, Quackenbush J, Park BH, Kaya N. Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old. Mol Cancer. 2010;9:146. [PMID: 20540791 DOI: 10.1186/1476-4598-9-146] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
518 Vauthey J, Ribero D, Abdalla EK, Jonas S, Bharat A, Schumacher G, Lerut J, Chapman WC, Hemming AW, Neuhaus P. Outcomes of Liver Transplantation in 490 Patients with Hepatocellular Carcinoma: Validation of a Uniform Staging after Surgical Treatment. Journal of the American College of Surgeons 2007;204:1016-27. [DOI: 10.1016/j.jamcollsurg.2006.12.043] [Cited by in Crossref: 61] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
519 Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol. 2013;23:471-482. [PMID: 24018165 DOI: 10.1016/j.semcancer.2013.08.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
520 Turri JAO, Decimoni TC, Ferreira LA, Diniz MA, Haddad LBDP, Campolina AG. Higher MELD score increases the overall cost on the waiting list for liver transplantation: a micro-costing analysis based study. Arq Gastroenterol 2017;54:238-45. [DOI: 10.1590/s0004-2803.201700000-35] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
521 O'Connell TM. Recent advances in metabolomics in oncology. Bioanalysis. 2012;4:431-451. [PMID: 22394143 DOI: 10.4155/bio.11.326] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
522 Kern MA, Breuhahn K, Schuchmann M, Schirmacher P. [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology]. Pathologe 2007;28:261-8. [PMID: 17605064 DOI: 10.1007/s00292-007-0890-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
523 Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, Ness P, Gibble J, Kleiner DE, Ghany MG, Alter HJ. A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. J Infect Dis 2012;206:654-61. [PMID: 22740714 DOI: 10.1093/infdis/jis410] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
524 Khachatoorian R, Arumugaswami V, Ruchala P, Raychaudhuri S, Maloney EM, Miao E, Dasgupta A, French SW. A cell-permeable hairpin peptide inhibits hepatitis C viral nonstructural protein 5A-mediated translation and virus production. Hepatology. 2012;55:1662-1672. [PMID: 22183951 DOI: 10.1002/hep.25533] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
525 Ying M, Tu C, Ying H, Hu Y, He Q, Yang B. MSFTZ, a flavanone derivative, induces human hepatoma cell apoptosis via a reactive oxygen species- and caspase-dependent mitochondrial pathway. J Pharmacol Exp Ther 2008;325:758-65. [PMID: 18323457 DOI: 10.1124/jpet.107.135657] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
526 Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C, Lv Y, Zhou Z, Liu Z. Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget. 2015;6:4440-4450. [PMID: 25686836 DOI: 10.18632/oncotarget.2913] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
527 Yang H, Nie Y, Li Y, Wan YJ. Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp Biol Med (Maywood) 2010;235:32-9. [PMID: 20404016 DOI: 10.1258/ebm.2009.009252] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
528 Peng Q, Lao X, Chen Z, Lai H, Deng Y, Wang J, Mo C, Sui J, Wu J, Zhai L. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One. 2013;8:e82773. [PMID: 24376578 DOI: 10.1371/journal.pone.0082773] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
529 Dewdney B, Hebbard L. Implementing genetic screening for the management of hepatic disease. Hepatobiliary Surg Nutr 2017;6:359-62. [PMID: 29152490 DOI: 10.21037/hbsn.2017.07.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
530 Zhao H, Feng X, Han W, Diao Y, Han D, Tian X, Gao Y, Liu S, Zhu S, Yao C, Gu J, Sun C, Lei L. Enhanced binding to and killing of hepatocellular carcinoma cells in vitro by melittin when linked with a novel targeting peptide screened from phage display: ENHANCED BINDING TO AND KILLING OF HEPATOCELLULAR CARCINOMA CELLS. J Pept Sci 2013;19:639-50. [DOI: 10.1002/psc.2542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
531 Wedd JP, Nordstrom E, Nydam T, Durham J, Zimmerman M, Johnson T, Thomas Purcell W, Biggins SW. Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient. Liver Transpl. 2015;21:1543-1552. [PMID: 26457885 DOI: 10.1002/lt.24356] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
532 Abu El Makarem MA, Abdel-aleem A, Ali A, Saber R, Shatat M, Rahem DA, Sayed D. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Annals of Hepatology 2011;10:296-305. [DOI: 10.1016/s1665-2681(19)31541-8] [Cited by in Crossref: 40] [Article Influence: 4.0] [Reference Citation Analysis]
533 Flores YN, Zhang ZF, Bastani R, Leng M, Crespi CM, Ramírez-Palacios P, Stevens H, Salmerón J. Risk factors for liver disease among adults of Mexican descent in the United States and Mexico. World J Gastroenterol 2018; 24(37): 4281-4290 [PMID: 30310261 DOI: 10.3748/wjg.v24.i37.4281] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
534 Eslam M, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Use of HOMA-IR in hepatitis C. J Viral Hepat. 2011;18:675-684. [PMID: 21914084 DOI: 10.1111/j.1365-2893.2011.01474.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
535 Livramento Ad, Cordova CM, Spada C, Treitinger A. Seroprevalence of hepatitis B and C infection markers among children and adolescents in the southern Brazilian region. Rev Inst Med Trop Sao Paulo 2011;53:13-7. [PMID: 21412614 DOI: 10.1590/s0036-46652011000100003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
536 Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer 2013;109:2481-8. [PMID: 24084770 DOI: 10.1038/bjc.2013.564] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
537 Younossi ZM, Stepanova M. Hepatitis C virus infection, age, and Hispanic ethnicity increase mortality from liver cancer in the United States. Clin Gastroenterol Hepatol. 2010;8:718-723. [PMID: 20435163 DOI: 10.1016/j.cgh.2010.04.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
538 Takayasu K. Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective. Oncology 2011;81 Suppl 1:105-10. [PMID: 22212943 DOI: 10.1159/000333269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
539 Morisco F, Guarino M, Valvano MR, Auriemma F, Farinati F, Giannini EG, Ciccarese F, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Benvengù L, Gasbarrini A, Svegliati Baroni G, Foschi FG, Biasini E, Masotto A, Virdone R, Marra F, Caporaso N, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Metabolic disorders across hepatocellular carcinoma in Italy. Liver Int 2018;38:2028-39. [PMID: 29745475 DOI: 10.1111/liv.13877] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
540 Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, Negri E. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67:302-309. [PMID: 28336466 DOI: 10.1016/j.jhep.2017.03.011] [Cited by in Crossref: 271] [Cited by in F6Publishing: 280] [Article Influence: 67.8] [Reference Citation Analysis]
541 Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, Lemoine A, Bismuth H, Castaing D, Adam R. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010;10:129-137. [PMID: 20070666 DOI: 10.1111/j.1600-6143.2009.02750.x] [Cited by in Crossref: 175] [Cited by in F6Publishing: 155] [Article Influence: 15.9] [Reference Citation Analysis]
542 Zhong JH, Ma L, Wu LC, Zhao W, Yuan WP, Wu FX, Zhang ZM, Huang S, You XM, Li LQ. Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int J Clin Pract. 2012;66:21-27. [PMID: 22171902 DOI: 10.1111/j.1742-1241.2011.02814.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
543 Jagan S, Ramakrishnan G, Anandakumar P, Kamaraj S, Devaki T. Antiproliferative potential of gallic acid against diethylnitrosamine-induced rat hepatocellular carcinoma. Mol Cell Biochem 2008;319:51-9. [PMID: 18629614 DOI: 10.1007/s11010-008-9876-4] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 4.9] [Reference Citation Analysis]
544 Dong C, Yoon YH, Chen CM, Yi HY. Heavy alcohol use and premature death from hepatocellular carcinoma in the United States, 1999-2006. J Stud Alcohol Drugs 2011;72:892-902. [PMID: 22051203 DOI: 10.15288/jsad.2011.72.892] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
545 Lu H, Rogowskyj J, Yu W, Venkatesh A, Khan N, Nakagawa S, Goossens N, Koh AP, Higashi T, Gunasekaran G, Schwarz ME, Hiotis SP, Xu X, Kinney W, Hoshida Y, Block T, Cuconati A, Du Y. Novel substituted aminothiazoles as potent and selective anti-hepatocellular carcinoma agents. Bioorg Med Chem Lett 2016;26:5819-24. [PMID: 27793566 DOI: 10.1016/j.bmcl.2016.10.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
546 Singh S, Colonna G, Di Bernardo G, Bergantino F, Cammarota M, Castello G, Costantini S. The gene expression profiling of hepatocellular carcinoma by a network analysis approach shows a dominance of intrinsically disordered proteins (IDPs) between hub nodes. Mol Biosyst 2015;11:2933-45. [PMID: 26267014 DOI: 10.1039/c5mb00434a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
547 Meer AJ, Maan R, Knegt RJ, Veldt BJ. Natural History of HCV-induced Liver Disease. Curr Hepatitis Rep 2013;12:251-60. [DOI: 10.1007/s11901-013-0195-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
548 Lee JS. The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol 2015;21:220-9. [PMID: 26523267 DOI: 10.3350/cmh.2015.21.3.220] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 10.5] [Reference Citation Analysis]
549 Zhang Y, Lu Y, Zhang C, Huang D, Wu W, Zhang Y, Shen J, Cai Y, Chen W, Yao W. FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition. Int J Oncol 2018;52:1455-64. [PMID: 29568938 DOI: 10.3892/ijo.2018.4327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
550 Klein J, Korol R, Lo SS, Chu W, Lock M, Dorth JA, Ellis RJ, Mayr NA, Huang Z, Chung HT. Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma. Future Oncol 2014;10:2227-41. [PMID: 25471036 DOI: 10.2217/fon.14.167] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
551 García A, Ihrig MM, Fry RC, Feng Y, Xu S, Boutin SR, Rogers AB, Muthupalani S, Samson LD, Fox JG. Genetic susceptibility to chronic hepatitis is inherited codominantly in Helicobacter hepaticus-infected AB6F1 and B6AF1 hybrid male mice, and progression to hepatocellular carcinoma is linked to hepatic expression of lipogenic genes and immune function-associated networks. Infect Immun. 2008;76:1866-1876. [PMID: 18285497 DOI: 10.1128/IAI.01044-07] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
552 Iguchi T, Aishima S, Sanefuji K, Fujita N, Sugimachi K, Gion T, Taketomi A, Shirabe K, Maehara Y, Tsuneyoshi M. Both fibrous capsule formation and extracapsular penetration are powerful predictors of poor survival in human hepatocellular carcinoma: a histological assessment of 365 patients in Japan. Ann Surg Oncol. 2009;16:2539-2546. [PMID: 19533247 DOI: 10.1245/s10434-009-0453-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
553 Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, Volk ML. The Epidemiology of Cirrhosis in the United States: A Population-based Study. J Clin Gastroenterol. 2015;49:690-696. [PMID: 25291348 DOI: 10.1097/mcg.0000000000000208] [Cited by in Crossref: 341] [Cited by in F6Publishing: 164] [Article Influence: 68.2] [Reference Citation Analysis]
554 Brunt EM, Walsh SN, Hayashi PH, Labundy J, Di Bisceglie AM. Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma. Liver Int. 2007;27:662-671. [PMID: 17498252 DOI: 10.1111/j.1478-3231.2007.01470.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
555 Mccubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. Emerging Raf inhibitors. Expert Opinion on Emerging Drugs 2009;14:633-48. [DOI: 10.1517/14728210903232633] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
556 Chuang S, Vecchia CL, Boffetta P. Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Letters 2009;286:9-14. [DOI: 10.1016/j.canlet.2008.10.040] [Cited by in Crossref: 188] [Cited by in F6Publishing: 174] [Article Influence: 15.7] [Reference Citation Analysis]
557 Montella M, Polesel J, La Vecchia C, Maso LD, Crispo A, Crovatto M, Casarin P, Izzo F, Tommasi LG, Talamini R, Franceschi S. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer 2007;120:1555-9. [DOI: 10.1002/ijc.22509] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 4.9] [Reference Citation Analysis]
558 Freedman ND, Marrero JA. Can dietary fish intake prevent liver cancer? Gastroenterology 2012;142:1411-3. [PMID: 22542830 DOI: 10.1053/j.gastro.2012.04.038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
559 Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer. 2005;92:1862-1868. [PMID: 15870713 DOI: 10.1038/sj.bjc.6602590] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 7.2] [Reference Citation Analysis]
560 Hsu Y, Wu C, Lin J. Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma. Seminars in Oncology 2015;42:329-38. [DOI: 10.1053/j.seminoncol.2014.12.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
561 Fernández-Ruiz M, Guerra-Vales JM, Castelbón-Fernández FJ, Llenas-García J, Caurcel-Díaz L, Colina-Ruizdelgado F. Multiple primary malignancies in Spanish patients with hepatocellular carcinoma: analysis of a hospital-based tumor registry. J Gastroenterol Hepatol 2009;24:1424-30. [PMID: 19486257 DOI: 10.1111/j.1440-1746.2009.05793.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
562 Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Chen DS, Yu CY, Wen CL, Lu FJ, Chow LP. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics. 2006;6:2865-2873. [PMID: 16586433 DOI: 10.1002/pmic.200500488] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 5.0] [Reference Citation Analysis]
563 Lee S, Lee MJ, Zhang J, Yu GR, Kim DG. C-terminal-truncated HBV X promotes hepato-oncogenesis through inhibition of tumor-suppressive β-catenin/BAMBI signaling. Exp Mol Med 2016;48:e275. [PMID: 27909336 DOI: 10.1038/emm.2016.107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
564 Bhat M, Skill N, Marcus V, Deschenes M, Tan X, Bouteaud J, Negi S, Awan Z, Aikin R, Kwan J, Amre R, Tabaries S, Hassanain M, Seidah NG, Maluccio M, Siegel P, Metrakos P. Decreased PCSK9 expression in human hepatocellular carcinoma. BMC Gastroenterol 2015;15:176. [PMID: 26674961 DOI: 10.1186/s12876-015-0371-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
565 Spangenberg HC, Thimme R, Blum HE. Evolving therapies in the treatment of hepatocellular carcinoma. Biologics 2008;2:453-62. [PMID: 19707376 DOI: 10.2147/btt.s3254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
566 Chan TH, Lin CH, Qi L, Fei J, Li Y, Yong KJ, Liu M, Song Y, Chow RK, Ng VH. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut. 2014;63:832-843. [PMID: 23766440 DOI: 10.1136/gutjnl-2012-304037] [Cited by in Crossref: 122] [Cited by in F6Publishing: 115] [Article Influence: 15.3] [Reference Citation Analysis]
567 Wu R, Ding W, Liu T, Zhu H, Hu Y, Yang B, He Q. XN05, a novel synthesized microtubule inhibitor, exhibits potent activity against human carcinoma cells in vitro. Cancer Letters 2009;285:13-22. [DOI: 10.1016/j.canlet.2009.04.042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
568 Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int. 2005;25:696-703. [PMID: 15998418 DOI: 10.1111/j.1478-3231.2005.01139.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 4.8] [Reference Citation Analysis]
569 Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Desanto JL, Curto TM, Wright EC; HALT-C Trial Group. Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Aliment Pharmacol Ther 2009;29:589-601. [PMID: 19053983 DOI: 10.1111/j.1365-2036.2008.03908.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
570 Lin H, Ha NB, Ahmed A, Ayoub W, Daugherty TJ, Lutchman GA, Garcia G, Nguyen MH. Both HCV and HBV are major causes of liver cancer in Southeast Asians. J Immigr Minor Health. 2013;15:1023-1029. [PMID: 23864445 DOI: 10.1007/s10903-013-9871-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
571 Tumanova UN, Shchegolev AI. Vascularization of hepatocellular carcinoma. Arkh patol 2015;77:50. [DOI: 10.17116/patol201577250-55] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
572 Villanueva A, Newell P, Hoshida Y. Inherited hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2010;24:725-34. [PMID: 20955973 DOI: 10.1016/j.bpg.2010.07.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
573 Ali AH, Tabibian JH, Nasser-Ghodsi N, Lennon RJ, DeLeon T, Borad MJ, Hilscher M, Silveira MG, Carey EJ, Lindor KD. Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. Hepatology 2018;67:2338-51. [PMID: 29244227 DOI: 10.1002/hep.29730] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 18.0] [Reference Citation Analysis]
574 Abrams P, Marsh JW. Current approach to hepatocellular carcinoma. Surg Clin North Am. 2010;90:803-816. [PMID: 20637949 DOI: 10.1016/j.suc.2010.04.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
575 Gonzalez SA, Fiel MI, Sauk J, Canchis PW, Liu RC, Chiriboga L, Yee HT, Jacobson IM, Talal AH. Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection. J Viral Hepat 2009;16:141-8. [PMID: 19175868 DOI: 10.1111/j.1365-2893.2008.01052.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
576 Zhou Q, Wang Y, Wang J, Liu Y, Qi D, Yao W, Jiang H, Li T, Huang K, Zhang W, Huo X. Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Medicine (Baltimore) 2021;100:e24940. [PMID: 33725855 DOI: 10.1097/MD.0000000000024940] [Reference Citation Analysis]
577 Xiong W, Cheeney G, Kim S, Kolesnikova V, Henninger B, Alexander J, Swanson PE, Upton MP, Truong CD, Yeh MM. Radiologically Undetected Hepatocellular Carcinoma in Patients Undergoing Liver Transplantation: An Immunohistochemical Correlation With LI-RADS Score. Am J Surg Pathol 2017;41:1466-72. [PMID: 28914714 DOI: 10.1097/PAS.0000000000000955] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
578 Elam MB, Cowan GS Jr, Rooney RJ, Hiler ML, Yellaturu CR, Deng X, Howell GE, Park EA, Gerling IC, Patel D, Corton JC, Cagen LM, Wilcox HG, Gandhi M, Bahr MH, Allan MC, Wodi LA, Cook GA, Hughes TA, Raghow R. Hepatic gene expression in morbidly obese women: implications for disease susceptibility. Obesity (Silver Spring) 2009;17:1563-73. [PMID: 19265796 DOI: 10.1038/oby.2009.49] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
579 Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology. 2009;50:387-392. [PMID: 19591128 DOI: 10.1002/hep.23000] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 5.7] [Reference Citation Analysis]
580 Liu CJ, Kao JH. Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chin Med Assoc. 2007;70:141-145. [PMID: 17475593 DOI: 10.1016/s1726-4901(09)70346-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
581 Chiappini F. Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol. 2012;2012:684802. [PMID: 22690340 DOI: 10.1155/2012/684802] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
582 Lai JP, Sandhu DS, Moser CD, Cazanave SC, Oseini AM, Shire AM, Shridhar V, Sanderson SO, Roberts LR. Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo. J Hepatol. 2009;50:1112-1121. [PMID: 19376607 DOI: 10.1016/j.jhep.2008.12.031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
583 Shih YL, Hsieh CB, Yan MD, Tsao CM, Hsieh TY, Liu CH, Lin YW. Frequent concomitant epigenetic silencing of SOX1 and secreted frizzled-related proteins (SFRPs) in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:551-559. [PMID: 23215838 DOI: 10.1111/jgh.12078] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
584 Todo S, Furukawa H, Tada M; Japanese Liver Transplantation Study Group. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2007;13:S48-S54. [PMID: 17969069 DOI: 10.1002/lt.21334] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis]
585 Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis. 2006;42:82-91. [PMID: 16323096 DOI: 10.1086/498512] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
586 Yang X, Wang D, Dong W, Song Z, Dou K. Expression and modulation of Na(+) /H(+) exchanger 1 gene in hepatocellular carcinoma: A potential therapeutic target. J Gastroenterol Hepatol. 2011;26:364-370. [PMID: 21261728 DOI: 10.1111/j.1440-1746.2010.06382.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
587 Kakehashi A, Inoue M, Wei M, Fukushima S, Wanibuchi H. Cytokeratin 8/18 overexpression and complex formation as an indicator of GST-P positive foci transformation into hepatocellular carcinomas. Toxicol Appl Pharmacol 2009;238:71-9. [PMID: 19409407 DOI: 10.1016/j.taap.2009.04.018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
588 Dorfman JD, Schulick R, Choti MA, Geschwind JFH, Kamel I, Torbenson M, Thuluvath PJ. Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States. World J Gastroenterol 2007; 13(5): 781-784 [PMID: 17278203 DOI: 10.3748/wjg.v13.i5.781] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
589 Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L. Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2012;9:530-538. [PMID: 22710573 DOI: 10.1038/nrgastro.2012.114] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 10.0] [Reference Citation Analysis]
590 Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, Lau CK, Li MLY, Tam KH, Lam CT, Poon RTP, Fan ST. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008;47:919-28. [DOI: 10.1002/hep.22082] [Cited by in Crossref: 251] [Cited by in F6Publishing: 243] [Article Influence: 19.3] [Reference Citation Analysis]
591 Goh WW, Lee YH, Zubaidah RM, Jin J, Dong D, Lin Q, Chung MC, Wong L. Network-based pipeline for analyzing MS data: an application toward liver cancer. J Proteome Res 2011;10:2261-72. [PMID: 21410269 DOI: 10.1021/pr1010845] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
592 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 10.5] [Reference Citation Analysis]
593 Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, McClintick JN, Edenberg HJ, Li L, Tavis JE, Howell C, Belle SH. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 2007;81:3391-401. [PMID: 17267482 DOI: 10.1128/JVI.02640-06] [Cited by in Crossref: 95] [Cited by in F6Publishing: 54] [Article Influence: 6.8] [Reference Citation Analysis]
594 Hu J, Ludgate L. HIV-HBV and HIV-HCV coinfection and liver cancer development. Cancer Treat Res. 2007;133:241-252. [PMID: 17672044 DOI: 10.1007/978-0-387-46816-7_9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
595 Malik AA, Phanus-Umporn C, Schaduangrat N, Shoombuatong W, Isarankura-Na-Ayudhya C, Nantasenamat C. HCVpred: A web server for predicting the bioactivity of hepatitis C virus NS5B inhibitors. J Comput Chem 2020;41:1820-34. [PMID: 32449536 DOI: 10.1002/jcc.26223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
596 Liu YJ, Zhou Y, Yeh MM. Recurrent genetic alterations in hepatitis C-associated hepatocellular carcinoma detected by genomic microarray: a genetic, clinical and pathological correlation study. Mol Cytogenet. 2014;7:81. [PMID: 25469175 DOI: 10.1186/s13039-014-0081-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
597 Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. Hepatology. 2006;43:S145-S150. [PMID: 16447291 DOI: 10.1002/hep.21063] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 6.8] [Reference Citation Analysis]
598 Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F; EUROCARE Working Group. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 2007;102:1661-70; quiz 1660, 1671. [PMID: 17555459 DOI: 10.1111/j.1572-0241.2007.01337.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 90] [Article Influence: 7.1] [Reference Citation Analysis]
599 Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev. 2006;32:28-44. [PMID: 16337744 DOI: 10.1016/j.ctrv.2005.10.004] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
600 Davis GL, Alter MJ, El–serag H, Poynard T, Jennings LW. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. Gastroenterology 2010;138:513-521.e6. [DOI: 10.1053/j.gastro.2009.09.067] [Cited by in Crossref: 649] [Cited by in F6Publishing: 613] [Article Influence: 59.0] [Reference Citation Analysis]
601 Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, Kaseb A, Curley SA, Vauthey JN. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer. 2008;123:1883-1891. [PMID: 18688864 DOI: 10.1002/ijc.23730] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 4.7] [Reference Citation Analysis]
602 Kolly P, Dufour JF. Surveillance for Hepatocellular Carcinoma in Patients with NASH. Diagnostics (Basel). 2016;6. pii:E22. [PMID: 27338480 DOI: 10.3390/diagnostics6020022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
603 Matos JM, Witzmann FA, Cummings OW, Schmidt CM. A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States. J Surg Res 2009;155:237-43. [PMID: 19535095 DOI: 10.1016/j.jss.2008.06.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
604 Facciuto ME, Singh MK, Rochon C, Sharma J, Gimenez C, Katta U, Moorthy CR, Bentley-Hibbert S, Rodriguez-Davalos M, Wolf DC. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol. 2012;105:692-698. [PMID: 21960321 DOI: 10.1002/jso.22104] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.3] [Reference Citation Analysis]
605 Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2017;15:1791-9. [PMID: 28579181 DOI: 10.1016/j.cgh.2017.05.036] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
606 Liu Y, Lin J. Blocking the IL-6-STAT3 signaling pathway: potential liver cancer therapy. Future Oncol 2011;7:161-4. [PMID: 21345134 DOI: 10.2217/fon.10.183] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
607 Borie F, Trétarre B, Bouvier A, Faivre J, Binder F, Launoy G, Delafosse P, Tissot J, Peng J, Grosclaude P, Guizard A, Gras-aygon C. Primitive liver cancers: epidemiology and geographical study in France. European Journal of Gastroenterology & Hepatology 2009;21:984-9. [DOI: 10.1097/meg.0b013e3283293783] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
608 Maturen KE, Nghiem HV, Marrero JA, Hussain HK, Higgins EG, Fox GA, Francis IR. Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique. AJR Am J Roentgenol. 2006;187:1184-1187. [PMID: 17056903 DOI: 10.2214/ajr.05.1347] [Cited by in Crossref: 95] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
609 Seitz HK, Stickel F. Ethanol and Hepatocarcinogenesis. In: Watson RR, Preedy VR, Zibadi S, editors. Alcohol, Nutrition, and Health Consequences. Totowa: Humana Press; 2013. pp. 411-27. [DOI: 10.1007/978-1-62703-047-2_32] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
610 Ishikawa T. Radiofrequency ablation is justified for elderly patients with hepatocellular carcinoma: Editorial. Hepatology Research 2010;40:954-5. [DOI: 10.1111/j.1872-034x.2010.00725.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
611 Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652-657. [PMID: 20346533 DOI: 10.1016/j.jhep.2009.12.028] [Cited by in Crossref: 231] [Cited by in F6Publishing: 221] [Article Influence: 21.0] [Reference Citation Analysis]
612 Poordad F, Castro RE, Asatryan A, Aguilar H, Cacoub P, Dieterich D, Marinho RT, Carvalho A, Siddique A, Hu YB, Charafeddine M, Bondin M, Khan N, Cohen DE, Felizarta F. Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials. J Viral Hepat 2020;27:497-504. [PMID: 31954087 DOI: 10.1111/jvh.13261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
613 Chen CT, Chen JY, Wang JH, Chang KC, Tseng PL, Kee KM, Chen PF, Tsai LS, Chen SC, Lin SC, Lu SN. Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan. Kaohsiung J Med Sci 2013;29:451-9. [PMID: 23906236 DOI: 10.1016/j.kjms.2012.12.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
614 Ryu SH, Chung YH, Lee H, Kim JA, Shin HD, Min HJ, Seo DD, Jang MK, Yu E, Kim KW. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology. 2008;47:929-936. [PMID: 18306220 DOI: 10.1002/hep.22124] [Cited by in Crossref: 63] [Cited by in F6Publishing: 68] [Article Influence: 4.8] [Reference Citation Analysis]
615 Miamen AG, Dong H, Roberts LR. Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer. 2012;1:226-237. [PMID: 24159587 DOI: 10.1159/000343837] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
616 Liu Y, He J, Li C, Benitez R, Fu S, Marrero J, Lubman DM. Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res. 2010;9:798-805. [PMID: 19961239 DOI: 10.1021/pr900715p] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 4.9] [Reference Citation Analysis]
617 De Luna W, Sze DY, Ahmed A, Ha BY, Ayoub W, Keeffe EB, Cooper A, Esquivel C, Nguyen MH. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant. 2009;9:1158-1168. [PMID: 19344435 DOI: 10.1111/j.1600-6143.2009.02576.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 86] [Article Influence: 7.7] [Reference Citation Analysis]
618 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol 2019; 25(13): 1550-1559 [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 37] [Article Influence: 22.0] [Reference Citation Analysis]
619 Shebl FM, El-Kamary SS. Diabetes mellitus, obesity, and hepatocellular carcinoma: the jury is still out. Am J Gastroenterol 2010;105:2116-7. [PMID: 20818365 DOI: 10.1038/ajg.2010.184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
620 Civan JM. Liver Transplantation for HCC: The Milan Criteria. In: Doria C, editor. Contemporary Liver Transplantation. Cham: Springer International Publishing; 2016. pp. 1-19. [DOI: 10.1007/978-3-319-05543-5_11-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
621 Larson AM. The epidemiology of hepatocellular carcinoma in hcv. Curr hepatitis rep 2005;4:145-52. [DOI: 10.1007/s11901-005-0030-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
622 Requarth J. Image-Guided Palliative Care Procedures. Surgical Clinics of North America 2011;91:367-402. [DOI: 10.1016/j.suc.2010.12.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
623 van den Bos IC, Hussain SM, Dwarkasing RS, Hop WC, Zondervan PE, de Man RA, IJzermans JN, Walker CW, Krestin GP. MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging. 2007;26:1548-1555. [PMID: 17968956 DOI: 10.1002/jmri.21046] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 4.6] [Reference Citation Analysis]
624 Reimer P, Vosshenrich R. Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent. Biologics 2010;4:199-212. [PMID: 20714357 DOI: 10.2147/btt.s6479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
625 Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418-1424. [PMID: 18848905 DOI: 10.1016/j.cgh.2008.08.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 118] [Article Influence: 10.7] [Reference Citation Analysis]
626 Knobler H, Malnick S. Hepatitis C and insulin action: An intimate relationship. World J Hepatol 2016; 8(2): 131-138 [PMID: 26807209 DOI: 10.4254/wjh.v8.i2.131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
627 Riehle KJ, Yeh MM, Yu JJ, Kenerson HL, Harris WP, Park JO, Yeung RS. mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma. Mod Pathol. 2015;28:103-110. [PMID: 24925055 DOI: 10.1038/modpathol.2014.78] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
628 Barr J, Vázquez-Chantada M, Alonso C, Pérez-Cormenzana M, Mayo R, Galán A, Caballería J, Martín-Duce A, Tran A, Wagner C. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res. 2010;9:4501-4512. [PMID: 20684516 DOI: 10.1021/pr1002593] [Cited by in Crossref: 111] [Cited by in F6Publishing: 105] [Article Influence: 11.1] [Reference Citation Analysis]
629 Bishayee A, Waghray A, Barnes KF, Mbimba T, Bhatia D, Chatterjee M, Darvesh AS. Suppression of the Inflammatory Cascade is Implicated in Resveratrol Chemoprevention of Experimental Hepatocarcinogenesis. Pharm Res 2010;27:1080-91. [DOI: 10.1007/s11095-010-0144-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
630 Huang H, Zhang XF, Zhou HJ, Xue YH, Dong QZ, Ye QH, Qin LX. Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection. Cancer Sci. 2010;101:1314-1319. [PMID: 20345480 DOI: 10.1111/j.1349-7006.2010.01524.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
631 Chochi Y, Kawauchi S, Nakao M, Furuya T, Hashimoto K, Oga A, Oka M, Sasaki K. A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study. J Pathol. 2009;217:677-684. [PMID: 19097070 DOI: 10.1002/path.2491] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
632 Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007;13:252-9. [PMID: 17452018 DOI: 10.1016/j.molmed.2007.04.002] [Cited by in Crossref: 338] [Cited by in F6Publishing: 325] [Article Influence: 24.1] [Reference Citation Analysis]
633 Chaerkady R, Harsha HC, Nalli A, Gucek M, Vivekanandan P, Akhtar J, Cole RN, Simmers J, Schulick RD, Singh S. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. J Proteome Res. 2008;7:4289-4298. [PMID: 18715028 DOI: 10.1021/pr800197z] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 7.8] [Reference Citation Analysis]
634 Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V, Dimitriadis G. Pathways and targets in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014;12:1347-57. [DOI: 10.1586/era.12.113] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
635 Blonski W, Reddy KR. Hepatitis C Virus Infection and Hepatocellular Carcinoma. Clinics in Liver Disease 2008;12:661-74. [DOI: 10.1016/j.cld.2008.03.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
636 Zubaidah RM, Tan GS, Tan SBE, Lim SG, Lin Q, Chung MCM. 2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. Proteomics 2008;8:5086-96. [DOI: 10.1002/pmic.200800322] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
637 Koniaris LG, Levi DM, Pedroso FE, Franceschi D, Tzakis AG, Santamaria-Barria JA, Tang J, Anderson M, Misra S, Solomon NL, Jin X, DiPasco PJ, Byrne MM, Zimmers TA. Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma? Ann Surg 2011;254:527-37; discussion 537-8. [PMID: 21865950 DOI: 10.1097/SLA.0b013e31822ca66f] [Cited by in Crossref: 77] [Cited by in F6Publishing: 34] [Article Influence: 7.7] [Reference Citation Analysis]
638 Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: Current status. World J Radiol. 2010;2:417-424. [PMID: 21179308 DOI: 10.4329/wjr.v2.ill.417] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
639 Suk FM, Lien GS, Huang WJ, Chen CN, Lu SY, Yang YC, Yan MD, Liang YC. A Taiwanese Propolis Derivative Induces Apoptosis through Inducing Endoplasmic Reticular Stress and Activating Transcription Factor-3 in Human Hepatoma Cells. Evid Based Complement Alternat Med 2013;2013:658370. [PMID: 24222778 DOI: 10.1155/2013/658370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
640 Kong L, Zhou Y, Bu H, Lv T, Shi Y, Yang J. Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice. J Exp Clin Cancer Res 2016;35:131. [PMID: 27589954 DOI: 10.1186/s13046-016-0412-1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 60] [Article Influence: 10.6] [Reference Citation Analysis]
641 Xu X, Zou H, Luo L, Wang X, Wang G. MicroRNA-9 exerts antitumor effects on hepatocellular carcinoma progression by targeting HMGA2. FEBS Open Bio 2019;9:1784-97. [PMID: 31408273 DOI: 10.1002/2211-5463.12716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
642 Vezali E, Aghemo A, Lampertico P, Colombo M. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? Clin Res Hepatol Gastroenterol 2011;35:455-64. [PMID: 21435968 DOI: 10.1016/j.clinre.2011.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
643 Morise Z, Kawabe N, Tomishige H, Nagata H, Kawase J, Arakawa S, Yoshida R, Isetani M. Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol 2014; 20(39): 14381-14392 [PMID: 25339825 DOI: 10.3748/wjg.v20.i39.14381] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
644 Yip-Schneider MT, Doyle CJ, McKillop IH, Wentz SC, Brandon-Warner E, Matos JM, Sandrasegaran K, Saxena R, Hennig ME, Wu H, Waters JA, Klein PJ, Froehlich JC, Schmidt CM. Alcohol induces liver neoplasia in a novel alcohol-preferring rat model. Alcohol Clin Exp Res 2011;35:2216-25. [PMID: 21790668 DOI: 10.1111/j.1530-0277.2011.01568.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
645 Yamasaki T, Hamabe S, Saeki I, Harima Y, Yamaguchi Y, Uchida K, Terai S, Sakaida I. A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. J Gastroenterol 2011;46:359-66. [DOI: 10.1007/s00535-010-0306-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
646 Venkatesan AM, Gervais DA, Mueller PR. Percutaneous radiofrequency thermal ablation of primary and metastatic hepatic tumors: current concepts and review of the literature. Semin Intervent Radiol. 2006;23:73-84. [PMID: 21326722 DOI: 10.1055/s-2006-939843] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
647 Okuda H. Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:161-73. [PMID: 17223503 DOI: 10.1016/j.bpg.2006.07.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
648 Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME. Clinical Utility of AFP-L3% Measurement in North American Patients with HCV-Related Cirrhosis. Am J Gastroenterology 2007;102:2196-205. [DOI: 10.1111/j.1572-0241.2007.01405.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 6.2] [Reference Citation Analysis]
649 Chen F, Beezhold K, Castranova V. JNK1, a potential therapeutic target for hepatocellular carcinoma. Biochim Biophys Acta 2009;1796:242-51. [PMID: 19591900 DOI: 10.1016/j.bbcan.2009.06.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
650 Ohki T, Tateishi R, Shiina S, Sato T, Masuzaki R, Yoshida H, Kanai F, Obi S, Yoshida H, Omata M. Obesity did not diminish the efficacy of percutaneous ablation for hepatocellular carcinoma. Liver Int 2007;27:360-7. [DOI: 10.1111/j.1478-3231.2006.01420.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
651 Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;CD001199. [PMID: 19160192 DOI: 10.1002/14651858.cd001199.pub2.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
652 Ocama P, Nambooze S, Opio CK, Shiels MS, Wabinga HR, Kirk GD. Trends in the incidence of primary liver cancer in Central Uganda, 1960-1980 and 1991-2005. Br J Cancer 2009;100:799-802. [PMID: 19174820 DOI: 10.1038/sj.bjc.6604893] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
653 Bugianesi E. Late complications of NASH: a challenge for hepatologists. Journal of Hepatology 2005;42:784-5. [DOI: 10.1016/j.jhep.2005.02.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
654 Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212-223. [PMID: 21386812 DOI: 10.1038/nrgastro.2011.21] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 9.3] [Reference Citation Analysis]
655 Narayanan G, Froud T, Suthar R, Barbery K. Irreversible electroporation of hepatic malignancy. Semin Intervent Radiol 2013;30:67-73. [PMID: 24436519 DOI: 10.1055/s-0033-1333655] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
656 Zidan A, Scheuerlein H, Schüle S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon. 2012;12:e6894. [PMID: 23233864 DOI: 10.5812/hepatmon.6894] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
657 Satoskar R, Reau N. Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force. Hepatology 2013;58:422-7. [PMID: 23460345 DOI: 10.1002/hep.26349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
658 Sicklick JK. Correcting the misnomers of epithelial–mesenchymal relations. Journal of Surgical Research 2013;182:36-9. [DOI: 10.1016/j.jss.2012.02.063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]